UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended April 30, 20172018

 

Commission File No. 000-51128

 

POLARITYTE, INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE 06-1529524
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)

 

404I-T Hadley Road1960 S 4250 W

S. Plainfield, New Jersey 07080Salt Lake City, UT 84104

(Address of principal executive offices)

 

Registrant’s Telephone Number, Including Area Code:(732) 225-8910(385) 237-2279

 

 

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.4.05 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer[  ] Accelerated filer[  ]
Non-accelerated filer[  ](Do not check if smaller reporting company)Smaller reporting company[X]
Emerging growth company[  ]   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

As of June 5, 2017,13, 2018, there were 5,876,95221,304,370 shares of the Registrant’s common stock outstanding.

 

 

 

   
 

 

INDEX

 

 Page
PART I - FINANCIAL INFORMATION 
  
Item 1. Financial Statements: 
Condensed Consolidated Balance Sheets as of April 30, 20172018 (unaudited) and October 31, 2016201713
Condensed Consolidated Statements of Operations for the three months and six months ended April 30, 2018 and 2017 and 2016 (unaudited)24
Condensed Consolidated Statement of Changes in Stockholders’ Equity for the six months ended April 30, 20172018 (unaudited)35
Condensed Consolidated Statements of Cash Flows for the six months ended April 30, 2018 and 2017 and 2016 (unaudited)46
Notes to Condensed Consolidated Financial Statements (unaudited)57
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations19
Item 3. Quantitative and Qualitative Disclosures about Market Risk2423
Item 4. Controls and Procedures2423
  
PART II - OTHER INFORMATION 
  
Item 1. Legal Proceedings24
Item 1A. Risk Factors2524
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds2527
Item 3. Defaults Upon Senior Securities2527
Item 4. Mine Safety Disclosures2527
Item 5. Other Information2527
Item 6. Exhibits2527
SIGNATURES2628

 

 -i- 
 

 

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

 

POLARITYTE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

 

 April 30, October 31, 
 2017  2016  April 30, 2018  October 31, 2017 
  (Unaudited)       (Unaudited)     
ASSETS                
        
Current assets:                
Cash and cash equivalents $4,777  $6,523  $37,838  $17,667 
Accounts receivable  65   113 
Capitalized software development costs and license fees  -   50 
Prepaid expenses and other current assets  326   47   294   237 
Receivable from Zift  45   60 
Total current assets  5,168   6,733   38,177   17,964 
Non-current assets:        
Property and equipment, net  1,878   18   6,342   2,173 
Security deposits - non-current  137   - 
Receivable from Zift, non-current  -   15 
Total non-current assets  6,479   2,188 
TOTAL ASSETS $7,046  $6,751  $44,656  $20,152 
                
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                
Current liabilities:                
Accounts payable and accrued expenses $1,409  $1,284  $3,007  $1,939 
Warrant liability  -   70 
Warrant liability and embedded derivative  -   13,502 
Total current liabilities  1,409   1,354   3,007   15,441 
Total liabilities  1,409   1,354   3,007   15,441 
                
Commitments and Contingencies                
                
Redeemable convertible preferred stock - Series F – 0 and 6,455 shares authorized, issued and outstanding at April 30, 2018 and October 31, 2017; liquidation preference - $0 and $17,750.  -   4,541 
        
STOCKHOLDERS’ EQUITY:                
Convertible preferred stock – 10,000,000 shares authorized, 3,936,732 and 7,374,454 shares issued and outstanding at April 30, 2017 and October 31, 2016, aggregate liquidation preference $2,585 and $4,854, respectively  111,948   10,153 
Common stock — $.001 par value; 250,000,000 shares authorized; 5,723,104 and 2,782,963 shares issued and outstanding at April 30, 2017 and October 31, 2016, respectively  6   3 
Convertible preferred stock – 10,000,000 and 9,993,545 shares authorized, 0 and 3,230,655 shares issued and outstanding at April 30, 2018 and October 31, 2017, aggregate liquidation preference $0 and $2,140, respectively  -   109,995 
Common stock - $.001 par value; 250,000,000 shares authorized; 18,843,488 and 6,515,524 shares issued and outstanding at April 30, 2018 and October 31, 2017, respectively  19   7 
Additional paid-in capital  137,880   123,417   326,343   149,173 
Accumulated deficit  (244,197)  (128,176)  (284,713)  (259,005)
Total stockholders’ equity  5,637   5,397   41,649   170 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $7,046  $6,751  $44,656  $20,152 

 

See accompanying notes to condensed consolidated financial statements.

 

 13 
 

 

POLARITYTE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except share and per share amounts)

 

  For the three months ended  For the six months ended 
  April 30,  April 30, 
  2017  2016  2017  2016 
Net revenues $259  $412  $415  $1,003 
Cost of sales                
Product costs  -   1   -   1 
Software development costs and license fees  -   124   -   182 
   -   125   -   183 
Gross profit  259   287   415   820 
Operating costs and expenses                
Product research and development  18   20   38   55 
Research and development – intellectual property acquired  104,693   -   104,693   - 
Selling and marketing  (7)  19   24   42 
General and administrative  5,817   1,319   11,496   2,441 
Depreciation and amortization  101   7   184   14 
   110,622   1,365   116,435   2,552 
Operating loss  (110,363)  (1,078)  (116,020)  (1,732)
Other expenses (income)                
Interest income  (3)  (3)  (7)  (10)
Change in fair value of warrant liability  -   26   8   26 
Loss before income taxes  (110,360)  (1,101)  (116,021)  (1,748)
Income taxes  -   -   -   - 
Net loss  (110,360)  (1,101)  (116,021)  (1,748)
Special cash dividend attributable to preferred stockholders  -   -   -   (6,002)
Net loss attributable to common stockholders $(110,360) $(1,101) $(116,021) $(7,750)
                 
Net loss per share, basic and diluted: $(23.50) $(0.58) $(28.93) $(4.41)
Weighted average shares outstanding, basic and diluted:  4,695,298   1,882,483   4,009,853   1,757,209 

See accompanying notes to condensed consolidated financial statements.

POLARITYTE, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited, in thousands, except share and per share amounts)

   Preferred Stock   Common Stock   Additional Paid-in   Accumulated   Total Stockholders’ 
   Number    Amount    Number    Amount   Capital   Deficit   Equity 
Balance as of October 31, 2016  7,374,454  $10,153   2,782,963  $3  $123,417  $(128,176) $5,397 
Issuance of common stock in connection with:                            
Conversion of Series A preferred stock to common stock  (3,336,700)  (816)  613,423   1   815   -   - 
Conversion of Series B preferred stock to common stock  (6,092)  (514)  101,540   -   514   -   - 
Conversion of Series C preferred stock to common stock  (5,648)  (441)  96,346   -   441   -   - 
Conversion of Series D preferred stock to common stock  (96,332)  (1,127)  160,551   -   1,127   -   - 
Issuance of Series E preferred stock for research and development intellectual property  7,050   104,693   -   -   -   -   104,693 
Proceeds from option exercises  -   -   121,698   -   588   -   588 
Warrant exchange to common stock  -   -   56,250   -   78   -   78 
 Stock-based compensation expense  -   -   1,031,000   1   8,623   -   8,624 
Shares issued for cash  -   -   759,333   1   2,277   -   2,278 
Net loss  -   -   -   -   -   (116,021)  (116,021)
Balance as of April 30, 2017  3,936,732  $111,948   5,723,104  $6  $137,880  $(244,197) $5,637 

See accompanying notes to condensed consolidated financial statements.

POLARITYTE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

  

For the six months ended

April 30,

 
  2017  2016 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss $(116,021) $(1,748)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization  184   14 
Stock based compensation expense  8,624   993 
Research and development – intellectual property acquired  104,693   - 
Amortization of capitalized software development costs and license fees  50   85 
Change in fair value of warrant liability  8   26 
Offering costs expensed  -   21 
Changes in operating assets and liabilities:        
Accounts receivable  48   (132)
Capitalized software development costs and license fees  -   9 
Prepaid expenses and other current assets  (279)  (77)
Accounts payable and accrued expenses  42   (190)
Payable to Zift  -   (10)
Net cash used in operating activities  (2,651)  (1,009)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of property and equipment  (1,961)  - 
Net cash used in investing activities  (1,961)  - 
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Special cash dividend  -   (10,000)
Proceeds from stock options exercised  588   129 
Net proceeds from the sale of common stock and warrants  -   1,406 
Payments to Zift  -   (233)
Proceeds from the sale of common stock  2,278   - 
Net cash provided by (used in) financing activities  2,866   (8,698)
         
Net decrease in cash and cash equivalents  (1,746)  (9,707)
Cash and cash equivalents — beginning of period  6,523   17,053 
Cash and cash equivalents — end of period $4,777  $7,346 
         
SUPPLEMENTAL CASH FLOW INFORMATION        
Cash paid during the period for income taxes $-  $- 
         
Supplemental schedule of non-cash investing and financing activities:        
Conversion of Series A preferred stock to common stock $816  $147 
Conversion of Series B preferred stock to common stock $514  $- 
Conversion of Series C preferred stock to common stock $441  $- 
Conversion of Series D preferred stock to common stock $1,127  $140 
Unpaid liability for acquisition of property and equipment $83  $- 
Warrant exchange for common stock shares $78  $- 
Common stock shares and warrants issued for offering costs $-  $75 
  For the three months ended  For the six months ended 
  April 30,  April 30, 
  2018  2017  2018  2017 
Net revenues $3  $-  $16  $- 
Cost of sales  1   -   2   - 
Gross profit  2   -   14   - 
Operating costs and expenses                
Product research and development  5,621   -   12,223   - 
Research and development - intellectual property acquired  -   104,693   -   104,693 
General and administrative  5,938   5,686   16,836   10,911 
   11,559   110,379   29,059   115,604 
Other (expenses) income                
Interest income  18   3   43   7 
Change in fair value of derivatives  440   -   3,814   (8)
Loss on extinguishment of warrant liability  (520)  -   (520)  - 
Net loss from continuing operations  (11,619)  (110,376)  (25,708)  (115,605)
Gain (loss) from discontinued operations  -   16   -   (416)
Net loss  (11,619)  (110,360)  (25,708)  (116,021)
Deemed dividend – accretion of discount on Series F preferred stock  (386)  -   (1,290)  - 
Deemed dividend – exchange of Series F preferred stock  (7,057)  -   (7,057)  - 
Cumulative dividends on Series F preferred stock  (98)  -   (373)  - 
Net loss attributable to common stockholders $(19,160) $(110,360) $(34,428) $(116,021)
                 
Net loss per share, basic and diluted:                
Loss from continuing operations $(0.89) $(23.51) $(2.63) $(28.83)
Gain (loss) from discontinued operations  -   0.01   -   (0.10)
Deemed dividend – accretion of discount on preferred stock  (0.03)  -   (0.13)  - 
Deemed dividend – exchange of Series F preferred stock  (0.54)  -   (0.72)  - 
Cumulative dividends on Series F preferred stock  (0.01)  -   (0.04)  - 
Net loss attributable to common stockholders $(1.47) $(23.50) $(3.52) $(28.93)
Weighted average shares outstanding, basic and diluted:  13,055,314   4,695,298   9,781,962   4,009,853 

 

See accompanying notes to condensed consolidated financial statements.

 

 4 
 

 

POLARITYTE, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited, in thousands, except share and per share amounts)

  Preferred Stock  Common Stock  Additional Paid-in  Accumulated  Total Stockholders’ 
  Number  Amount  Number  Amount  Capital  Deficit  Equity 
Balance as of October 31, 2017  3,230,655  $109,995   6,515,524  $7  $149,173  $(259,005) $170 
Issuance of common stock in connection with:                            
Conversion of Series A preferred stock to common stock  (3,146,671)  (769)  713,036   1   768   -   - 
Conversion of Series B preferred stock to common stock  (47,689)  (4,020)  794,820   1   4,019   -   - 
Conversion of Series C preferred stock to common stock  (2,578)  (201)  59,950   -   201   -   - 
Conversion of Series D preferred stock to common stock  (26,667)  (312)  44,445   -   312   -   - 
Conversion of Series E preferred stock to common stock  (7,050)  (104,693)  7,050,000   7   104,686   -   - 
Exchange of Series F preferred stock and dividends to common stock  -   -   1,003,391   1   13,060   -   13,061 
Extinguishment of warrant liability  -   -   151,871   -   3,045   -   3,045 
Option exercises  -   -   25,417   -   91   -   91 
Proceeds received from issuance of common stock, net of issuance costs of $2,782  -   -   2,335,937   2   34,593   -   34,595 
Stock-based compensation expense  -   -   137,387   -   17,752   -   17,752 
Deemed dividend - accretion of discount on Series F preferred stock  -   -   -   -   (1,290)  -   (1,290)
Cumulative dividends on Series F preferred stock  -   -   -   -   (373)  -   (373)
Series F preferred stock dividends paid in common stock  -   -   11,710   -   306   -   306 
Net loss  -   -   -   -   -   (25,708)  (25,708)
Balance as of April 30, 2018  -  $-   18,843,488  $19  $326,343  $(284,713) $41,649 

See accompanying notes to condensed consolidated financial statements.

5

POLARITYTE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

  

For the six months ended

April 30,

 
  2018  2017 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss $(25,708) $(116,021)
Loss from discontinued operations  -   (416)
Loss from continuing operations  (25,708)  (115,605)
Adjustments to reconcile net loss from continuing operations to net cash used in continuing operating activities:        
Loss on extinguishment of warrant liability  520   - 
Depreciation and amortization  606   173 
Stock based compensation expense  17,752   7,780 
Research and development - intellectual property acquired  -   104,693 
Change in fair value of derivatives  (3,814)  8 
Changes in operating assets and liabilities:        
Prepaid expenses and other current assets  16   - 
Security deposits - non-current  (137)  (279)
Accounts payable and accrued expenses  737   32 
Net cash used in continuing operating activities  (10,028)  (3,198)
Net cash provided by discontinued operating activities  -   547 
Net cash used in operating activities  (10,028)  (2,651)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of property and equipment  (4,517)  (1,961)
Net cash used in continuing investing activities  (4,517)  (1,961)
Net cash provided by discontinued investing activities  30   - 
Net cash used in investing activities  (4,487)  (1,961)
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from stock options exercised  91   588 
Net proceeds from the sale of common stock  34,595   2,278 
Net cash provided by financing activities  34,686   2,866 
         
Net increase (decrease) in cash and cash equivalents  20,171   (1,746)
Cash and cash equivalents - beginning of period  17,667   6,523 
Cash and cash equivalents - end of period $37,838  $4,777 
         
Supplemental schedule of non-cash investing and financing activities:        
Conversion of Series A preferred stock to common stock $769  $816 
Conversion of Series B preferred stock to common stock $4,020  $514 
Conversion of Series C preferred stock to common stock $201  $441 
Conversion of Series D preferred stock to common stock $312  $1,127 
Conversion of Series E preferred stock to common stock $104,693  $- 
Exchange of Series F preferred stock for common stock $13,061  $- 
Extinguishment of warrant liability $2,525  $- 
Unpaid liability for acquisition of property and equipment $385  $83 
Warrant exchange for common stock shares $-  $78 
Deemed dividend - accretion of discount on preferred stock $1,290  $- 
Cumulative dividends on Series F preferred stock $373  $- 
Series F preferred stock dividends paid in common stock $306  $- 

See accompanying notes to condensed consolidated financial statements.

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

1. PRINCIPAL BUSINESS ACTIVITY AND BASIS OF PRESENTATION

 

PolarityTE, Inc. is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

Asset Acquisition and Name Change.Discontinued Operations.On December 1, 2016,June 23, 2017, the Company sold Majesco Entertainment Company, (the “Company”) entered into an agreement to acquire the assetsa Nevada corporation and wholly-owned subsidiary of PolarityTE, Inc., (the “Seller”), a regenerative medicine company. The asset acquisition was subject to shareholder approval, which was received on March 10, 2017. In January, 2017, the Company changed its name(“Majesco Sub”), to “PolarityTE, Inc.”

On April 7, 2017,Zift Interactive LLC, a Nevada limited liability company (“Zift”), pursuant to a purchase agreement. Pursuant to the Sellerterms of the agreement, the Company sold 100% of the issued 7,050and outstanding shares of the Company’s newly authorized Series E Preferred Stock (the “Preferred Shares”) convertible into an aggregatecommon stock of 7,050,000 sharesMajesco to Zift, including all of the Company’s common stockright, title and interest in and to Majesco Sub’s business of developing, publishing and distributing video game products through mobile and online digital downloading. Pursuant to the terms of the agreement, the Company will receive total cash consideration of approximately $100,000 ($5,000 upon signing the agreement and 19 additional monthly payments of $5,000) plus contingent consideration based on net revenues with a fair value of approximately $104.7 million which is equal to 7,050,000 common shares times $14.85 (the closing price of the Company’s common stock as$0. As of April 7, 2017). Since the assets purchased were in-process research and development assets, the total purchase price was immediately expensed as research and development – intellectual property acquired since they have no alternative future use.

On December 1, 2016,30, 2018, the Company hired Dr. Denver Lough as Chief Executive Officer, Chief Scientific Officerreceived $55,000 in cash consideration and Chairman of our Board of Directors and Dr. Ned Swanson as Chief Operating Officer of the Company. Until their hiring both doctors were associated with Johns Hopkins University, Baltimore, Maryland, as full-time residents.

The doctors lead the Company’s current efforts focused on scientific research and development and in this regard on December 1, 2016, the Company leased laboratory space and purchased laboratory equipment in Salt Lake City, Utah. Subsequent expenditures during January 2017 include approximately $1.4 million for the purchase of medical equipment, including microscopes for high end real-time imaging of cells and tissues required for tissue engineering and regenerative medicine research. The Company has added additional facilities, and established university and scientific relationships and collaborations in order to pursue its business. None of these activities were performed by Dr. Lough or Dr. Swanson prior to December 1, 2016 in connection with their university positions or privately.

Dr. Lough is the named inventor under a pending patent application for a novel regenerative medicine and tissue engineering platform filed in the United States and elsewhere. The Company believes that its future success depends significantly on its ability to protect its inventions and technology. Accordingly, the Company is seeking to acquire the pending patent application. Prior to December 1, 2016, no employees, consultants or partners engaged in any business activity related to the patent application and no licenses or contracts were granted related to the patent application, other than professional services related to preparation and filing of the patent. On December 1, 2016, Dr. Lough assigned the patent application as well as all related intellectual property to a newly-formed Nevada corporation, Polarityte, Inc. (“Polarity NV”), and the Company entered into an Agreement and Plan of Reorganization (the “Agreement”) with Polarity NV and Dr. Lough.

As a result, at closing, the patent application would be owned by the Company without the need for further assignments or recordation with the Patent Trademark Office.

There was never any intent to acquire an ongoing business and no ongoing business was acquired. The asset is preserved in a stand-alone entity merely as a vehicle to provide the Company a seamless means to acquire the asset (a patent application) without undue cost, expense and time. Polarity NV has never had employees and, therefore, no employees were acquired in the transaction.

The Company adopted ASU 2017-01,Business Combinations (Topic 805), Clarifying the Definition of a Business, during the first quarter of fiscal 2017. In accordance with ASU 2017-01 we analyzed the above transaction as follows:

Step 1 - Is substantially all the fair value of the gross assets acquired concentrated in a single (group of similar) identifiable asset(s)? – The Company has a proposal to acquire a single intellectual property asset and no employees on the acquisition date.

Step 2 - Evaluate whether an input and a substantive process exists? Does the set have outputs? – The set does not yet have outputs, as Polarity NV’s intellectual property does not generate any revenue. Without outputs, the set requires employees that form an organized workforce with skills, knowledge, or experience to perform an acquired process that is critical to the ability to create outputs to qualify as a business. Polarity NV never had any employees or workforce. On December 1, 2016, prior to any Polarity NV acquisition, the Company hired Denver Lough as its Chief Executive and Chief Scientific Officer and Edward Swanson as Chief Operating Officer (“COO”). Both of these executives were employed full-time by Johns Hopkins University and were not employed by Polarity NV. In December 2016, the Company established a clinical advisory board and added three members in December 2016 and three more in January 2017. Establishing the clinical advisory board and hiring a COO are critical to establishing at the Company for the first time a workforce that has the knowledge and experience to obtain regulatory approval of the Company’s intellectual property. Therefore, the acquisition of an intellectual property asset and no employees from Polarity NV on April 7, 2017 did not represent the acquisition of an organized workforce with the necessary skills and experience to create outputs.

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

General.The accompanying consolidated financial statements present the financial results of PolarityTE, Inc. and its wholly owned subsidiaries Polarity NV and Majesco Europe Limited. Majesco Europe Limited was dissolved during the year ended October 31, 2016.$45,000 remains receivable.

 

Segments.The Company’s operations involve dissimilar products which are managed separately. Accordingly, it operates in two segments: 1) video games and 2) regenerative medicine.

Video Games

The Company is a providerWith the sale of video game products primarily for the casual-game consumer and has published video games for interactive entertainment hardware platforms, including Nintendo’s DS, 3DS, Wii and WiiU, Sony’s PlayStation 3 and 4, or PS3 and PS4, Microsoft’s Xbox 360 and Xbox One and the personal computer, or PC. The Company sells its products through digital distribution.

The Company’s video game titles are targeted at various demographics at a range of price points. Due to the larger budget requirements for developing and marketing premium console titles for core gamers, the Company has focusedMajesco Sub on publishing lower-cost games targeting casual-game consumers and independent game developer fans. In some instances, the Company’s titles are based on licenses of well-known properties and, in other cases, original properties. The Company enters into agreements with content providers and video game development studios for the creation of its video games.

The Company currently has no plans or understandings to discontinue or divest its current existing software business although the Company has received inquiries from prospective purchasers of various assets and the business. The Company may determine to dispose of such business in whole or in part, or discontinue such business, and may reevaluate from time to time although presently 4 employees continue to be employed in direct activities related to such software business and administration and the Company is continuing to generate revenue from its sales of digital online games. The Company is diversifying its business model in an attempt to mitigate risk associated with focusing on one industry and increase the overall value of the Company for its shareholders.

Regenerative Medicine

Through its regenerative medicine efforts, the Company is developing the proprietary tissue engineering platform invented by Dr. Denver Lough to translate regenerative products into clinical application. Preliminarily, the technological platform has demonstrated the potential capacity to grow fully functional tissue across the entire spectrum of the musculoskeletal and integumentary systems, including skin, muscle, bone, cartilage, peripheral nerve, fat, and fascia. Preliminary results indicate it has applications across solid organ and specialty tissue regeneration as well, including bowel, liver, kidney, and urethra. The product furthest in the development pipeline is an autologous (tissue from the patient themselves) skin regeneration construct, SkinTETM, to regenerate fully functional skin with all of its layers, including epidermis, dermis, hypodermis, and all appendages including hair and glands. SkinTETM is preparing for clinical testing and market entry, and targeting a global wound care market of $40 billion. The platform provides a pipeline of products to follow in parallel, with plans for serial clinical and market entry, and each addressing separate and similarly sized potential markets. The Company’s approach seeks to benefit from fewer regulatory and capital barriers to market entry, avoiding the long timelines associated with three phase trials and their associated costs seen with other competing technologies and therapeutics. The regenerative medicine business model being pursued takes advantage of the smaller regulatory hurdles, with streamlined product development from cell/tissue in vitro and ex vivo testing, to small and large animal preclinical models, manufacturing technology transfer, and ultimately clinical application and market entry occurring in a mapped out stepwise fashion for each product. Although skin regeneration and wound care is a robust market in and of itself, the platform technology provides a base that the Company believes will support a strategy to build a company that can diversify and grow continuously.

NASDAQ listing. On January 6, 2017, PolarityTE, Inc., was notified by The NASDAQ Stock Market, LLC of failure to comply with Nasdaq Listing Rule 5605(b)(1) which requires that a majority of the directors comprising the Company’s Board of Directors be considered “independent”, as defined under the Rule. The notice had no immediate effect on the listing or trading of the Company’s common stock on The NASDAQ Capital Market and the common stock continued to trade on The NASDAQ Capital Market under the symbol “COOL”.

On February 22,June 23, 2017, the Company regained compliance with Listing Rule 5605(b)(1), the independent director requirement for continued listing on The NASDAQ Stock Market, with the appointment of Mr. Steve Gorlin and Dr. Jon Mogford, and the matter is now closed. PolarityTE’s common stock will continue to be listed on The NASDAQ Capital Market.

Major customers. Sony, Microsoft, Entrophy and Valve accounted for 33%, 29%, 13%, and 11%, respectively, of sales for the six months ended April 30, 2017. Microsoft, Sony, and Valve accounted for 40%, 28%, and 18%, respectively, of sales for the six months ended April 30, 2016. Sony and Microsoft accounted for 43% and 23%, respectively, of accounts receivable as of April 30, 2017.

6

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Concentrations.The Company develops and distributes video game software for proprietary platforms under licenses from Nintendo, Sony and Microsoft, which must be periodically renewed. The Company’s agreements with these manufacturers also grant them certain control over the Company’s products. In addition, for the six months ended April 30, 2017 and 2016 sales of the Company’s Zumba Fitness games accounted for approximately 11% and 10% of net revenues, respectively.solely operates in its Regenerative Medicine segment.

 

The accompanying interim condensed consolidated financial statements of the Company are unaudited, but in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the results for the interim period. Accordingly, they do not include all information and notes required by generally accepted accounting principles for complete financial statements. The Company’s financial results are impacted by the seasonality of the retail selling season and the timing of the release of new titles. The results of operations for interim periods are not necessarily indicative of results to be expected for the entire fiscal year. The balance sheet at October 31, 20162017 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the year ended October 31, 20162017 filed with the Securities and Exchange Commission on Form 10-K on DecemberJanuary 30, 2016.2018.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation.The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Polarity NVsubsidiaries: PolarityTE, Inc., a Nevada corporation, and Majesco Europe Limited.Sub (through the date sold). Majesco Europe LimitedSub was dissolved during the year ended October 31, 2016.sold on June 23, 2017. Significant intercompany accounts and transactions have been eliminated in consolidation.

 

Revenue Recognition. The Company’s software products are sold exclusively as downloads of digital content for which the consumer takes possession of the digital content for a fee. Revenue from product downloads is generally recognized when the download is made available (assuming all other recognition criteria are met).

Cash and cash equivalents.Cash Equivalents. Cash equivalents consist of highly liquid investments with original maturities of three months or less at the date of purchase. At various times, the Company has deposits in excess of the Federal Deposit Insurance Corporation limit. The Company has not experienced any losses on these accounts.

 

Accounts Receivable and Accounts Payable and Accrued Expenses. The carrying amounts of accounts receivable and accounts payable and accrued expenses approximate fair value as these accounts are largely current and short term in nature.

Allowance for Doubtful Accounts. The Company recognizes an allowance for losses on accounts receivable for estimated probable losses. The allowance is based on historical experiences, current aging of accounts, and other expected future write-offs, including specific identifiable customer accounts considered at risk or uncollectible. Any related expense associated with an allowance for doubtful accounts is recognized as general and administrative expense. As of April 30, 2017 and 2016, there was no allowance for doubtful accounts.

Capitalized Software Development Costs and License Fees. Software development costs include fees in the form of milestone payments made to independent software developers and licensors. Software development costs are capitalized once technological feasibility of a product is established and management expects such costs to be recoverable against future revenues. For products where proven game engine technology exists, this may occur early in the development cycle. Technological feasibility is evaluated on a product-by-product basis. Amounts related to software development that are not capitalized are charged immediately to product research and development costs. Commencing upon a related product’s release, capitalized costs are amortized to cost of sales based upon the higher of (i) the ratio of current revenue to total projected revenue or (ii) straight-line charges over the expected marketable life of the product.

Prepaid license fees represent license fees to owners for the use of their intellectual property rights in the development of the Company’s products. Minimum guaranteed royalty payments for intellectual property licenses are initially recorded as an asset (prepaid license fees) and a current liability (accrued royalties payable) at the contractual amount upon execution of the contract or when specified milestones or events occur and when no significant performance remains with the licensor. Licenses are expensed to cost of sales at the higher of (i) the contractual royalty rate based on actual sales or (ii) an effective rate based upon total projected revenue related to such license. Capitalized software development costs and prepaid license fees are classified as non-current if they relate to titles for which the Company estimates the release date to be more than one year from the balance sheet date.

7

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The amortization period for capitalized software development costs and prepaid license fees is usually no longer than one year from the initial release of the product. If actual revenues or revised forecasted revenues fall below the initial forecasted revenue for a particular license, the charge to cost of sales may be larger than anticipated in any given quarter. The recoverability of capitalized software development costs and prepaid license fees is evaluated quarterly based on the expected performance of the specific products to which the costs relate. When, in management’s estimate, future cash flows will not be sufficient to recover previously capitalized costs, the Company expenses these capitalized costs to “cost of sales-software development costs and license fees,” in the period such a determination is made. These expenses may be incurred prior to a game’s release for games that have been developed. If a game is cancelled prior to completion of development and never released to market, the amount is expensed to operating costs and expenses. If the Company was required to write off licenses, due to changes in market conditions or product acceptance, its results of operations could be materially adversely affected.

Costs of developing online free-to-play social games, including payments to third-party developers, are expensed as research and development expenses. Revenue from these games is largely dependent on players’ future purchasing behavior in the game and currently the Company cannot reliably project that future net cash flows from developed games will exceed related development costs.

Prepaid license fees and milestone payments made to the Company’s third-party developers are typically considered non-refundable advances against the total compensation they can earn based upon the sales performance of the products. Any additional royalty or other compensation earned beyond the milestone payments is expensed to cost of sales as incurred.

 

Property and Equipment. Property and equipment is stated at cost. Depreciation and amortization is being provided for by the straight-line method over the estimated useful lives of the assets, generally fiverange from three to eight years. Amortization of leasehold improvements is provided for over the shorter of the term of the lease or the life of the asset.

Capitalized Software Development Costs. Software development costs are capitalized once technological feasibility is established and management expects such costs to be recoverable against future revenues. Amounts related to software development that are not capitalized are charged immediately to expense. Capitalized costs are amortized straight-line over the expected life of the software.

 

Income Taxes. The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company evaluates the potential for realization of deferred tax assets at each quarterly balance sheet date and records a valuation allowance for assets for which realization is not more likely than not.

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

Stock Based Compensation. The Company measures all stock-based compensation to employees using a fair value method and records such expense in general and administrative and research and development expenses. Compensation expense for stock options with cliff vesting is recognized on a straight-line basis over the vesting period of the award, based on the fair value of the option on the date of grant. For stock options with graded vesting, the Company recognizes compensation expense over the service period for each separately vesting tranche of the award as though the award were in substance, multiple awards.

 

The fair value for options issued is estimated at the date of grant using a Black-Scholes option-pricing model. The risk-free rate is derived from the U.S. Treasury yield curve in effect at the time of the grant. The volatility factor is determined based on the Company’s historical stock prices.

 

The value of restricted stock and restricted stock unit grants is measured based on the fair market value of the Company’s common stock on the date of grant and amortized over the vesting period of, generally, six months to three years.

 

Loss Per Share. Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share excludes the potential impact of common stock options, unvested shares of restricted stock and outstanding common stock purchase warrants because their effect would be anti-dilutive due to our net loss.

 

Commitments and Contingencies. We are subject to claims and litigation in the ordinary course of our business. We record a liability for contingencies when the amount is both probable and reasonably estimable. We record associated legal fees as incurred.

 

Accounting for Warrants. The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging (“ASC 815”). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). In addition, under ASC 815, registered common stock warrants that require the issuance of registered shares upon exercise and do not expressly preclude an implied right to cash settlement are accounted for as derivative liabilities. The Company classifies these derivative warrant liabilities on the condensed consolidated balance sheet as a current liability.

 

8

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Change in Fair Value of Warrant Liability.Derivatives. The Company assessed the classification of common stock purchase warrants as of the date of each offering and determined that certain instruments met the criteria for liability classification. Accordingly, the Company classified the warrants as a liability at their fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised or expired, and any change in fair value is recognized as “change in fair value of warrant liability”derivatives” in the condensed consolidated statements of operations. The fair value of the warrants has as well as other derivatives have been estimated using a Monte-Carlo or Black-Scholes valuation model (see Note 7).model.

 

Reverse stock-splitRevenue Recognition.. On July 27, 2016, Majesco Entertainment The Company (the “Company”) filed a certificaterecognizes revenue upon the shipment of amendment (the “Amendment”) to its Restated Certificate of Incorporation with the Secretary of Stateproducts when each of the Statefollowing four criteria is met: (i) persuasive evidence of Delaware in order to effectuate a reverse stock split ofan arrangement exists; (ii) products are delivered; (iii) the Company’s issuedsales price is fixed or determinable; and outstanding common stock, par value $0.001 per share on a one (1) for six (6) basis, effective on July 29, 2016 (the “Reverse Stock Split”).(iv) collectability is reasonably assured.

 

The Reverse Stock Split was effective with The NASDAQ Capital Market (“NASDAQ”) at the open of business on August 1, 2016. The par value and other terms of Company’s common stock were not affected by the Reverse Stock Split. The Company’s post-Reverse Stock Split common stock has a new CUSIP number, 560690 406. The Company’s transfer agent, Equity Stock Transfer LLC, acted as exchange agent for the Reverse Stock Split.

As a result of the Reverse Stock Split, every six shares of the Company’s pre-Reverse Stock Split common stock was combined and reclassified into one share of the Company’s common stock. No fractional shares of common stock were issued as a result of the Reverse Stock Split. Stockholders who otherwise would be entitled to a fractional share shall receive a cash payment in an amount equal to the product obtained by multiplying (i) the closing sale price of our common stock on the business day immediately preceding the effective date of the Reverse Stock Split as reported on NASDAQ by (ii) the number of shares of our common stock held by the stockholder that would otherwise have been exchanged for the fractional share interest.

All common share and per share amounts have been restated to show the effect of the Reverse Stock Split.

Estimates.The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities or the disclosure of gain or loss contingencies at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Among the more significant estimates included in these financial statements are the recoverability of advance payments for capitalized software development costs and intellectual property licenses, the valuation of warrant liability, stock basedvaluation of derivative liability, stock-based compensation and the valuation allowances for deferred tax benefits. Actual results could differ from those estimates.

 

Recently Adopted Accounting Pronouncements

 

In August 2014,April 2016, the FASB issued ASU No. 2014-15,2016-09,DisclosureShare-Based Payment: Simplifying the Accounting for Share-Based Payments. The standard addresses several aspects of Uncertainties about an Entity’s Ability to Continuethe accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as a Going Concern (“ASU No. 2014-15”) that requires management to evaluate whether there are conditions and events that raise substantial doubt aboutwell as classification in the Company’s ability to continue as a going concern within one year after the financial statements are issued on both an interim and annual basis. Management is required to provide certain footnote disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.statement of cash flows. The Company adopted ASU No. 2014-15 on November 1, 20162016-09 during the first quarter of fiscal 2018 and its adoption did not havethe Company elected to account for forfeitures as they occur. The amendment was applied using a materialmodified retrospective transition method. The provisions of ASU 2016-09 had no impact on the Company’s consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-01,Business Combinations (Topic 805) Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company adopted this guidance effective November 1, 2016.

8

Recent Accounting Pronouncements.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update (“ASU”) creating a new Topic 606,Revenue from Contracts with Customers, which broadly establishes new standards for the recognition of certain revenue and updates related disclosure requirements. The update becomes effective for the Company on November 1, 2018. The Company is reviewing the potential impact of the statement on its financial position, results of operations, and cash flows.

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Recent Accounting Pronouncements.

 

In February 2016, FASB issued ASU No. 2016-02,Leases (Topic 842), which supersedes FASB ASC Topic 840,Leases (Topic 840)and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. When adopted,The Company is currently assessing the Company does not expectpotential impact of this guidance, but expects it to have a material impact on our financial statements.the Company’s balance sheet.

 

In March 2016,May 2017, the FASB issued ASU No. 2016-08, Revenue2017-09,from Contracts with CustomersCompensation-Stock Compensation (Topic 606)718): Principal versus Agent ConsiderationsScope of Modification Accounting. The purposeASU 2017-09 provides clarity and reduces both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, to a change to the terms or conditions of ASU No. 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. For public entities, thea share-based payment award. The amendments in ASU No. 2016-08 are2017-09 should be applied prospectively to an award modified on or after the adoption date. This ASU is effective for fiscal years, and interim and annual reporting periods within those years, beginning after December 15, 2017. The Company is currently assessing the potential impact of adopting ASU No. 2016-082017-09 on its condensed consolidated financial statements and related disclosures.

 

In March 2016,July 2017, the FASB issued ASU No. 2016-09,2017-11,Compensation-Stock CompensationEarnings Per Share (Topic 718)260), Improvements to Employee Share-Based PaymentDistinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815):I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception, (ASU 2017-11). Under ASU No. 2016-09, companies will no longer record excess tax benefitsPart I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain tax deficiencies in additional paid-in capital (“APIC”). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be eliminated. In addition, ASU No. 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize them. ASU No. 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Furthermore, ASU No. 2016-09 will increase the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee’s applicable jurisdiction(s). ASU No. 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current U.S. GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required.mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. This ASU areis effective for reportingfiscal years, and interim periods within those years, beginning after December 15, 2016, with early adoption permitted but all of the guidance must be adopted in the same period.2018. The Company is currently assessing the potential impact of adopting ASU 2017-11 on its financial statements and related disclosures.

In August 2016, the FASB issued ASU 2016-15,Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, which addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The adoption of this update is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, a new accounting standard that requires recognition of revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The FASB has also issued several updates to ASU No. 2016-092014-09. The new standard supersedes U.S. GAAP guidance on revenue recognition and requires the use of more estimates and judgments than the present standards. It also requires additional disclosures regarding the nature, amount, timing and uncertainty of cash flows arising from contracts with customers. Topic 606 is effective for our fiscal year 2019 beginning on November 1, 2018. The Company is currently evaluating the overall effect that the standard will have on its condensedour consolidated financial statements and accompanying notes to the consolidated financial statements.

 

In April 2016, the FASB issued ASU No. 2016-10,Revenue from Contracts with Customer3. The new guidance is an update to ASC 606 and provides clarity on: identifying performance obligations and licensing implementation. For public companies, ASU No. 2016-10 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. The Company is currently evaluating the impact that ASU No. 2016-10 will have on its condensed consolidated financial statements.LIQUIDITY

 

The Company has experienced net losses and negative cash flows from operations during each of the last two fiscal years. The Company has experienced negative cash flows from continuing operations of approximately $10.0 million for the six months ended April 30, 2018. Given these negative cash flows and forecasted increased spending, the continuation of the Company as a going concern is dependent upon continued financial support from its shareholders, potential collaborations, the ability of the Company to obtain necessary equity and/or debt financing to continue operations, and the attainment of profitable operations. The Company cannot make any assurances that additional financings will be available to it and, if available, completed on a timely basis, on acceptable terms or at all. If the Company is unable to complete a debt or equity offering, execute a collaboration arrangement or otherwise obtain sufficient financing when and if needed, it would negatively impact its business and operations and could also lead to the reduction or suspension of the Company’s operations and ultimately force the Company to cease operations.

3.POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

On April 12, 2018, the Company completed a public offering providing for the issuance and sale of 2,335,937 shares of the Company’s common stock, par value $0.001 per share, at an offering price of $16.00 per share, for net proceeds of approximately $34.6 million, after deducting offering expenses payable by the Company (see Note 7).

On June 7, 2018, the Company completed an underwritten offering with Cantor Fitzgerald & Co., as underwriter, providing for the issuance and sale of 2,455,882 shares of the Company’s common stock, par value $0.001 per share, at an offering price of $23.65 per share, for net proceeds of approximately $58 million, after deducting offering expenses payable by the Company (see Note 14).

4. PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consist of the following (in thousands):

 

  

April 30,

2017

  

October 31,

2016

 
Legal retainer $105  $- 
Prepaid insurance  151   22 
Tax receivable  -   18 
Other prepaids  38   - 
Deposits  32   - 
Other  -   7 
Total prepaid expenses and other current assets $326  $47 

10
  April 30, 2018  October 31, 2017 
Legal retainer $-  $15 
Prepaid insurance  121   69 
Other prepaids  149   126 
Other assets  24   27 
Total prepaid expenses and other current assets $294  $237 

 

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

4.5. PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net, consist of the following (in thousands):

 

 

April 30,

2017

 

October 31,

2016

  April 30, 2018  October 31, 2017 
Medical equipment $1,935  $-  $6,272  $2,418 
Computers and software  139   61   999   211 
Furniture and equipment  109   78   163   30 
Total property and equipment, gross  2,183   139   7,434   2,659 
Accumulated depreciation  (305)  (121)  (1,092)  (486)
Total property and equipment, net $1,878  $18  $6,342  $2,173 

Depreciation expense for the three months ended April 30, 2018 and 2017 was approximately $350,000 and $101,000, respectively. Depreciation expense for the six months ended April 30, 2018 and 2017 was approximately $606,000 and $184,000, respectively.

 

5.6. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses consist of the following (in thousands):

 

 

April 30,

2017

 

October 31,

2016

  April 30, 2018  October 31, 2017 
Accounts payable-trade $358  $130 
Royalties, fees and development  462   680 
Accounts payable $20  $25 
Due to Zift  -   36 
Medical study and supplies  48   362 
Medical equipment purchase  83   -   385   54 
Salaries and other compensation  500   463   637   574 
Legal and accounting  978   555 
Consulting  283   - 
Other accruals  6   11   656   333 
Total accounts payable and accrued expenses $1,409  $1,284  $3,007  $1,939 

 

Salaries and other compensation include accrued payroll expense and employer 401K plan contributions.

6. STOCKHOLDERS’ EQUITY

Convertible preferred stock as of April 30, 2017 consisted of the following (in thousands, except share amounts):

  Shares Authorized  Shares Issued and Outstanding  Net Carrying Value  Aggregate Liquidation Preference  Common Shares Issuable Upon Conversion 
Series A  8,830,000   3,801,458  $929  $2,585   861,664 
Series B  54,250   48,109   4,055   -   801,820 
Series C  26,000   20,115   1,569   -   467,791 
Series D  170,000   60,000   702   -   100,000 
Series E  7,050   7,050   104,693   -   7,050,000 
Other authorized, unissued  912,700   -   -   -   - 
Total  10,000,000   3,936,732  $111,948  $2,585   9,281,275 

Convertible preferred stock as of October 31, 2016 consisted of the following (in thousands, except share amounts):

  Shares Authorized  Shares Issued and Outstanding  Net Carrying Value  Aggregate Liquidation Preference  Common Shares Issuable Upon Conversion 
Series A  8,830,000   7,138,158  $1,745  $4,854   1,189,693 
Series B  54,250   54,201   4,569   -   903,362 
Series C  26,000   25,763   2,010   -   429,392 
Series D  170,000   156,332   1,829   -   260,553 
Other authorized, unissued  919,750   -   -   -   - 
Total  10,000,000   7,374,454  $10,153  $4,854   2,783,000 

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

7. PREFERRED SHARES AND COMMON SHARES

Common Stock Issuance

On April 12, 2018, the Company completed a public offering providing for the issuance and sale of 2,335,937 shares of the Company’s common stock, par value $0.001 per share, at an offering price of $16.00 per share, for net proceeds of approximately $34.6 million, after deducting offering expenses payable by the Company.

 

Exchange of 100% of Outstanding Series AF Preferred Stock Shares and Warrants

On September 20, 2017, the Company sold an aggregate of $17,750,000 worth of units (the “Units”) of the Company’s securities to accredited investors at a purchase price of $2,750 per Unit with each Unit consisting of (i) one share of the Company’s newly authorized 6% Series F Convertible Preferred Stock, par value $0.001 per share (the “Series F Preferred Shares”), which are each convertible into one hundred (100) shares of the Company’s common stock, and (ii) a two-year warrant to purchase up to 322,727 shares of the Company’s common stock, at an exercise price of $30.00 per share.

 

The Series AF Preferred Shares arewere convertible into shares of the Company’s common stock based on a conversion calculation equal to the stated value of such Series A Preferred Share, plus all accrued and unpaid dividends, if any, on such Series A Preferred Share, as of such date of determination, divided by the conversion price. The stated value of each Preferred Share is $0.68 and the initial conversion price is $4.08 (current conversion price is $3.00) per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. In addition, in the event the Company issues or sells, or is deemed to issue or sell, shares of its common stock at a per share price that is less than the conversion price then in effect, the conversion price shall be reduced to such lower price, subject to certain exceptions. Pursuant to the Certificate of Designations, Preferences and Rights of the 0% Series A Convertible Preferred Stock of PolarityTE, Inc., the Company is prohibited from incurring debt or liens, or entering into new financing transactions without the consent of the lead investor (as defined in the December Subscription Agreements) as long as any of the Series A Preferred Shares are outstanding. The Series A Preferred Shares bear no dividends.

The holders of Series A Preferred Shares shall vote together with the holders of common stock on all matters on an as if converted basis, subject to certain conversion and ownership limitations, and shall not vote as a separate class. Notwithstanding the foregoing, the conversion price for purposes of calculating voting power shall in no event be lower than $3.54 per share. At no time may all or a portion of the Series A Preferred Shares be converted if the number of shares of common stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of common stock owned by the holder at such time, the number of shares of common stock which would result in such Holder beneficially owning (as determined in accordance with Section 13(d) of the 1934 Act and the rules thereunder) more than 4.99% of all of the common stock outstanding at such time; provided, however, that the holder may waive the 4.99% limitation at which time he may not own beneficially own more than 9.99% of all the common stock outstanding at such time.

The Series A Preferred Shares do not represent an unconditional obligation to be settled in a variable number of shares of common stock, are not redeemable and do not contain fixed or indexed conversion provisions similar to debt instruments. Accordingly, the Series A Preferred Shares are considered equity hosts and recorded in stockholders’ equity.

The Company entered into separate Registration Rights Agreements with each Series A Preferred Shares Investor, (as amended on January 30, 2015 and March 31, 2015, the “December Registration Rights Agreement”). The Company agreed to use its best efforts to file by March 31, 2015 a registration statement covering the resale of the shares of common stock issuable upon exercise or conversion of the Series A Preferred Shares and to maintain its effectiveness until all such securities have been sold or may be sold without restriction under Rule 144 of the Securities Act. In the event the Company fails to satisfy its obligations under the December Registration Rights Agreements, the Company is required to pay to the Investors on a monthly basis an amount equal to 1% of the investors’ investment, up to a maximum of 12%. On March 31, 2015, the Company and the required holders of Series A Preferred Shares amended the registration rights agreement to extend the filing deadline for the registration statement to June 30, 2015.

Series B Preferred Shares

The Series B Preferred Shares are convertible into shares of common stock based on a conversion calculation equal to the stated value of such Series BF Preferred Shares, plus all accrued and unpaid dividends, if any, on such Series B Preferred Shares, as of such date of determination, divided by the conversion price. The stated value of each Preferred Share is $140.00 and the initial conversion price is $8.40 per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. The Company is prohibited from effecting a conversion of the Series B Preferred Shares to the extent that, as a result of such conversion, such holder would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the Series B Preferred Shares, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%. Subject to such beneficial ownership limitations, each holder is entitled to vote on all matters submitted to stockholders of the Company on an as converted basis, based on a conversion price of $8.40 per shares. The Series B Preferred Shares rank junior to the Series A Preferred Shares and bear no dividends. All of the convertible preferred shares do not represent an unconditional obligation to be settled in a variable number of shares, are not redeemable and do not contain fixed or indexed conversion provisions similar to debt instruments. Accordingly, the convertible preferred shares are considered equity hosts and recorded in stockholders’ equity.

12

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Series C Preferred Shares

The Series C Preferred Shares are convertible into shares of common stock based on a conversion calculation equal to the stated value of such Series C Preferred Shares, plus all accrued and unpaid dividends, if any, on such Series CF Preferred Shares, as of such date of determination, divided by the conversion price. The stated value of each Series CF Preferred Share is $120.00 per share,was $2,750 and the initial conversion price is $7.20 (current conversion price is $5.16)was $27.50 per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. In addition, in

On the eventtwo year anniversary of the initial issuance date, any Series F Preferred Shares outstanding and not otherwise already converted, shall, at the option of the holder, will either (i) automatically convert into common stock of the Company issues or sells, or is deemed to issue or sell, shares of common stock at a per share price that is less than the conversion price then in effect the conversion price shallor (ii) be reduced to such lower price, subject to certain exceptions and provided that the conversion price may not be reduced to less than $5.16, unless and until such time asrepaid by the Company obtains shareholder approval to allow for a lower conversion price. based on the stated value of such outstanding Series F Preferred Shares.

The Company is prohibited from effecting a conversion ofwarrants issued in connection with the Series CF Preferred Shares were determined to the extent that, as a result of such conversion, such May Investor would beneficially own more than 4.99% ofbe liabilities pursuant to ASC 815. The warrant agreement provides for an adjustment to the number of common shares issuable under the warrant and/or adjustment to the exercise price, including but not limited to, if: (a) the Company issues shares of common stock as a dividend or distribution to holders of its common stock; (b) the Company subdivides or combines its common stock (i.e., stock split); (c) adjustment of exercise price upon issuance of new securities at less than the exercise price. Under ASC 815, warrants that provide for down-round exercise price protection are recognized as derivative liabilities.

The conversion feature within the Series F Preferred Shares was determined to not be clearly and closely related to the identified host instrument and, as such, was recognized as a derivative liability measured at fair value pursuant to ASC 815.

The initial fair value of the warrants and bifurcated embedded conversion feature, estimated to be approximately $4.3 million and $9.3 million, respectively, was deducted from the gross proceeds of the Unit offering to arrive at the initial discounted carrying value of the Series F Preferred Shares. The resulting discount to the aggregate stated value of the Series F Preferred Shares of approximately $13.6 million will be recognized as accretion using the effective interest method similar to preferred stock dividends, over the two-year period prior to optional redemption by the holders.

On March 6, 2018, the Company entered into separate exchange agreements (the “Exchange Agreements”) with holders (each a “Holder”, and collectively the “Holders”) of 100% of the Company’s outstanding immediately after giving effectSeries F Preferred Shares, and the Company’s warrants to purchase shares of the Company’s common stock issued in connection with the Series F Preferred Shares (such “Warrants” and Series F Preferred Shares collectively referred to as the “Exchange Securities”) to exchange the Exchange Securities and unpaid dividends on the Series F Preferred Shares, for common stock (the “Exchange”).

The Exchange resulted in the following issuances: (A) all outstanding Series F Preferred Shares were converted into 972,070 shares of restricted common stock at an effective conversion price of $18.26 per share of common stock (the closing price of Common Stock on the NASDAQ Capital Market on February 26, 2018); (B) the right to receive 6% dividends underlying Series F Preferred Shares was terminated and in exchange 31,321 shares of restricted common stock were issued; (C) 322,727 Warrants to purchase common stock were exchanged for 151,871 shares of restricted common stock; and (D) the Holders of the Warrants relinquished any and all other rights pursuant to the Warrants, including exercise price adjustments.

As part of the Exchange, the Holders also relinquished any and all other rights related to the issuance of the Exchange Securities, the respective governing agreements and certificates of designation, including any related dividends, adjustment of conversion and exercise price, and repayment option. The existing registration rights agreement with the holders of the Series F Preferred Shares was also terminated and the holders of the Series F Preferred Shares waived the obligation of the Company to register the common shares issuable upon conversion of Series F Preferred Shares or upon exercise of the warrants, and waived any damages, penalties and defaults related to the Company failing to file or have declared effective a registration statement covering those shares.

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The exchange of all outstanding Series F Preferred Shares, and the holders’ right to receive 6% dividends, for common stock of the Company was recognized as follows:

Fair market value of 1,003,391 shares of common stock issued at $20.05 (Company’s closing stock price on March 5, 2018) in exchange for Series F Preferred Shares and accrued dividends $20,117,990 
Carrying value of Series F Preferred Shares at March 5, 2018, including dividends  (5,898,274)
Carrying value of bifurcated conversion option at March 5, 2018  (7,162,587)
Deemed dividend on Series F Preferred Shares exchange $7,057,129 

As the Warrants were classified as a liability, the exchange of the Warrants for common shares should be recognized as a liability extinguishment. As of March 5, 2018, the fair market value of the 151,871 common shares issued in the Exchange was $3,045,034 and the fair value of the common stock warrant liability was $2,525,567 resulting in a loss on extinguishment of warrant liability of $519,467 during the three and six months ended April 30, 2018.

The Company recognized accretion of the discount to the stated value of the Series F Preferred Shares of approximately $386,000 and $1,290,000 in the three months ended April 30, 2018 (through March 5, 2018) and six months ended April 30, 2018, respectively, as a reduction of additional paid-in capital and an increase in the carrying value of the Series F Preferred Shares. The accretion is presented in the Statement of Operations as a deemed dividend, increasing net loss to arrive at net loss attributable to common stockholders.

Preferred Stock Conversion and Elimination

On February 6, 2018, 15,756 shares of Series B Convertible Preferred Stock (“Series B Preferred Shares”) were converted into 262,606 shares of common stock.

On March 6, 2018, the Company received conversion notices (in accordance with original terms) from holders of 100% of the outstanding shares of Series A Convertible Preferred Stock (the “Series A Preferred Shares”), Series B Preferred Shares and Series E Convertible Preferred Stock (the “Series E Preferred Shares”) and issued an aggregate of 7,945,250 shares of common stock upon conversion of theto such holders.

The Series CE Preferred Shares which beneficial ownership limitation may be increasedwere held by Dr. Denver Lough, the holder up to, but not exceeding, 9.99%. Subject to the beneficial ownership limitations discussed previously, each holder is entitled to vote on all matters submitted to stockholders ofCompany’s Chief Executive Officer. On March 6, 2018, the Company and shall have the number of votes equal to the number of shares of common stock issuable upon conversion of such holder’s Series C Preferred Shares, based on a conversion price of $7.80 per share. The Series C Preferred Shares bear no dividends and shall rank junior to the Company’s Series A Preferred Shares but senior to the Company’s Series B Preferred Shares.

In connection with the sale of the Series C Preferred Shares, the Company also entered into separatea new registration rights agreementsagreement (the “May“Lough Registration Rights Agreement”) with each Investor. TheDr. Lough, pursuant to which the Company agreed to use its best efforts to file a registration statement to register the Shares and the common stock issuableresale of 7,050,000 shares of Common Stock issued upon the conversion of the Series CE Preferred Shares within thirty days following the Closing Date,six months, to cause such registration statement to be declared effective within ninety days ofby the Securities and Exchange Commission as promptly as possible following its filing day and, with certain exceptions set forth in the Lough Registration Rights Agreement, to maintain the effectiveness of the registration statement until all of such shares of common stock have been sold or are otherwise able to be sold pursuant to Rule 144 under the Securities Act without restriction. In the event the Company fails to satisfy its obligationsAny sales of shares under the Registration Rights Agreement, the Company is obligated to pay to the Investors on a monthly basis, an amount equal to 1% of the Investor’s investment, up to a maximum of 12%. Effective as of the original filing deadline of the registration statement are subject to certain limitations as specified with more particularity in the Company obtained the requisite approval from the Investors for the waiver of its obligations under the MayLough Registration Rights Agreement.

The Company evaluated the guidance ASC 480-10Distinguishing Liabilities In April 2018, Dr. Lough entered into a lock up agreement for 180 days, which prohibits him from Equity andASC 815-40Contracts in an Entity’s Own Equity to determine the appropriate classification of the instruments. The Series C Preferred Shares do not represent an unconditional obligation to be settled in a variable number ofselling any shares of common stock, are not redeemable and do not contain fixed or indexed conversion provisions similar to debt instruments. Accordingly, the Series C Preferred Shares are considered equity hosts and recorded in stockholders’ equity.

Series D Preferred Shares

The Preferred D Shares are convertible into shares of common stock based on a conversion calculation equal to the stated value of such Preferred D Shares, plus all accrued and unpaid dividends, if any, on such Preferred D Share, as of such date of determination, divided by the conversion price. The stated value Preferred D Shares is $1,000 per share and the initial conversion price is $600 per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. The Company is prohibited from effecting a conversion of the Preferred D Shares to the extent that as a result of such conversion, such investor would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon conversion of the Preferred D Shares. Upon 61 days written notice, the beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%. Except as otherwise required by law, holders of Series D Preferred Shares shall not have any voting rights. Pursuant to the Certificate of Designations, Preferences and Rights of the 0% Series D Convertible Preferred Stock, the Preferred D Shares bear no dividends and shall rank senior to the Company’s other classes of capital stock.

Series E Preferred Shares

The Preferred E Shares are convertible into shares of common stock based on a conversion calculation equal to the stated value of such Preferred E Shares, plus all accrued and unpaid dividends, if any as of such date of determination, divided by the conversion price. The stated value of each Preferred E Share is $1,000 and the initial conversion price is $1.00 per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. The Preferred E Shares, with respect to dividend rights and rights on liquidation, winding-up and dissolution, in each case will rank senior to the Company’s common stock and all other securities of the Company that do not expressly provide that such securities rank on parity with or senior to the Preferred E Shares. Until converted, each Preferred E Share is entitled to two votes for every share of common stock into which it is convertible on any matter submitted for a vote of stockholders. The Preferred E Shares participate on an “as converted” basis with all dividends declared on the Company’s common stock.

April 2016 Registered Common Stock and Warrant Offeringregistered until October 2018.

 

On April 13, 2016,March 7, 2018, the Company entered intofiled a Securities Purchase AgreementCertificate of Elimination with certain institutional investors providing for the issuanceSecretary of State of the State of Delaware terminating the Company’s Series A, Series B, Series C, Series D, Series E and sale bySeries F Preferred Stock. As a result, the Company of 250,000has 10,000,000 shares of the Company’s commonauthorized and unissued preferred stock par value $0.001 per share at an offering price of $6.00 per share, for net proceeds of $1.4 million after deducting placement agent fees and expenses. In addition, the Company soldwith no designation as to purchasers of common stock in this offering, warrants to purchase 187,500 shares of its common stock. The common shares and the Warrant Shares were offered by the Company pursuant to an effective shelf registration statement on Form S-3, which was initially filed with the Securities and Exchange Commission on October 22, 2015 and declared effective on December 7, 2015. The closing of the offering occurred on April 19, 2016.series.

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

Each Warrant is immediately exercisableConvertible preferred stock activity for two years, but not thereafter, at an exercise price of $6.90 per share. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of its warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to such exercise. The exercise price and number of warrants are subject to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization, reorganization or similar transaction. The Warrants were classified as liabilities and measured at fair value, with changes in fair value recognized in the Condensed Consolidated Statements of Operations in other expenses (income). The initial recognition of the Warrants resulted in an allocation of the net proceeds from the offering to a warrant liability of approximately $318,000, with the remainder being attributable to the common stock sold in the offering.

Preferred Share Conversion Activity

During the six months ended April 30, 2017, 3,336,700 shares2018 consisted of Convertible Preferred Stock Series A, 6,092 shares of Convertible Preferred Stock Series B, 5,648 shares of Convertible Preferred Stock Series C and 96,332 shares of Convertible Preferred Stock Series D were converted into 971,860 shares of common stock.the following:

 

During the six months ended April 30, 2016, 599,634 shares of Convertible Preferred Stock Series A and 12,001 shares of Convertible Preferred Stock Series D were converted into 119,941 shares of common stock.

  

Shares

Outstanding –
October 31, 2017

  First Quarter 2018 -Preferred Stock Conversions  First Quarter 2018 – Common Stock Shares Issued  Second Quarter 2018 -Preferred Stock Conversions and Series F Exchange  Second Quarter 2018 – Common Stock Shares Issued  Year to Date 2018 -Preferred Stock Conversions and Series F Exchange  Year to Date 2018 – Common Stock Shares Issued 
Series A  3,146,671   (1,544,572)  350,000   (1,602,099)  363,036   (3,146,671)  713,036 
Series B  47,689   -   -   (47,689)  794,820   (47,689)  794,820 
Series C  2,578   (2,578)  59,950   -   -   (2,578)  59,950 
Series D  26,667   (26,667)  44,445   -       (26,667)  44,445 
Series E  7,050   -   -   (7,050)  7,050,000   (7,050)  7,050,000 
Series F  6,455   -   -   (6,455)  972,070   (6,455)  972,070 
Total  3,237,110   (1,573,817)  454,395   (1,663,293)  9,179,926   (3,237,110)  9,634,321 

 

Common Stock

On January 4, 2016, the Company declared a special cash dividend of an aggregate of $10.0 million to holders of record on January 14, 2016 of its outstanding shares of: (i) common stock (ii) Series A Convertible Preferred Stock; (iii) Series B Convertible Preferred Stock; (iv) Series C Convertible Preferred Stock and (v) Series D Convertible Preferred Stock. The holders of record of the Company’s outstanding preferred stock participated in the dividend on an “as converted” basis. Approximately $6.0 million of the special cash dividend relates to preferred stock shares.

On January 6, 2016, certain employees exercised their options at $4.08 in exchange for the Company’s common stock for an aggregated amount of 31,656 shares.

On December 16, 2016, the Company sold an aggregate of 759,333 shares of its common stock to certain accredited investors pursuant to separate subscription agreements at a price of $3.00 per share for gross proceeds of $2.3 million.

On January 18, 2017, the Company entered into separate exchange agreements (each an “Exchange Agreement”) with certain accredited investors (the “Investors”) who purchased warrants to purchase shares of the Company’s common stock (the “Warrants”) pursuant to the prospectus dated April 13, 2016. In 2016, the Company issued 250,000 shares of the Company’s common stock and Warrants to purchase 187,500 shares of common stock (taking into account the reverse split of the Company’s common stock on a 1 for 6 basis effective with The NASDAQ Stock Market LLC on August 1, 2016). The common stock and Warrants were offered by the Company pursuant to an effective shelf registration statement. Under the terms of the Exchange Agreement, each Investor exchanged each Warrant it purchased in the Offering for 0.3 shares of common stock. Accordingly, the Company issued an aggregate of 56,250 shares of common stock in exchange for the return and cancellation of 187,500 Warrants.

During the six months ended April 30, 2017, certain employees exercised their options at a weighted-average exercise price of $4.83 in exchange for the Company’s common stock for an aggregated amount of 121,698 shares. The Company received approximately $588,000 from the exercise of stock options.

7.8. FAIR VALUE MEASUREMENTS

 

In accordance with ASC 820, Fair Value Measurements, financial instruments were measured at fair value using a three-level hierarchy which maximizes use of observable inputs and minimizes use of unobservable inputs:

 

Level 1: Observable inputs such as quoted prices in active markets for identical instruments
 
Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the market
 
Level 3: Significant unobservable inputs supported by little or no market activity. Financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, for which determination of fair value requires significant judgment or estimation.

 

In connection with the April 19, 2016 common stock offering of Units in September 2017, the Company issued warrants to purchase an aggregate of 187,500322,727 shares of common stock. These warrants were exercisable at $6.90$30.00 per share and expire on April 19, 2018. Thesein two years. The warrants were analyzed and it was determined that they require liability treatment.liabilities pursuant to ASC 815. The warrant agreement provided for an adjustment to the number of common shares issuable under the warrant and/or adjustment to the exercise price, including but not limited to, if: (a) the Company issues shares of common stock as a dividend or distribution to holders of its common stock; (b) the Company subdivides or combines its common stock (i.e., stock split); (c) adjustment of exercise price upon issuance of new securities at less than the exercise price. Under ASC 815, registered common stock warrants that require the issuance of registered shares uponprovide for down-round exercise and do not expressly preclude an implied right to cash settlementprice protection are accounted forrecognized as derivative liabilities.

The Series F Preferred Shares contained an embedded conversion feature that was not clearly and closely related to the identified host instrument and, as such, was recognized as a derivative liability measured at fair value. The Company classifiesclassified these derivative warrant liabilitiesderivatives on the condensed consolidated balance sheet as a current liability.

As noted in Note 7. above, both the warrants and the Series F Preferred Shares were exchanged for common stock on March 6, 2018.

The fair value of the bifurcated embedded conversion feature was estimated to be approximately $7.2 million and $9.2 million, respectively, at March 5, 2018 and October 31, 2017 as calculated using a Monte Carlo simulation with the following assumptions:

  Series F Conversion Feature 
  March 5, 2018  October 31, 2017 
Stock price $20.05  $25.87 
Exercise price $27.50  $27.50 
Risk-free rate  2.158%  1.581%
Volatility  88.2%  96.0%
Term  1.54   1.89 

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

The fair value of these warrantsthe warrant liability was estimated to be approximately $2.5 million and $4.3 million, respectively, at January 18, 2017March 5, 2018 and October 31, 2016 was determined to be approximately $78,000 and $70,000, respectively,2017 as calculated using Black-Scholesthe Monte Carlo simulation with the following assumptions: (1) stock price of $3.62 and $3.58, respectively; (2) a risk-free rate of 0.97% and 0.75%, respectively; and (3) an expected volatility of 68% and 61%, respectively.

  Warrant Liability 
  March 5, 2018  October 31, 2017 
Stock price $20.05  $25.87 
Exercise price $30.00  $30.00 
Risk-free rate  2.158%  1.581%
Volatility  88.2%  96.0%
Term  1.54   1.89 

 

Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. At

The fair value hierarchy of financial instruments, measured at fair value on a recurring basis on the consolidated balance sheets as of October 31, 2017 is as follows (in thousands):

  Fair Value Measurement as of October 31, 2017 
  Level 1  Level 2  Level 3  Total 
Liabilities                
Warrant liability $-  $-  $4,256  $4,256 
Derivative liability  -   -   9,246   9,246 
Total $-  $-  $13,502  $13,502 

As of April 30, 2017,2018, there waswere no warrant liability balance.outstanding financial instruments.

 

The following table sets forth the changes in the estimated fair value for our Level 3 classified derivative warrant liabilityliabilities (in thousands):

 

  Warrant Liability 
Fair value - October 31, 2016 $70 
Exchanged - January 18, 2017 (see Note 6)  (78)
Change in fair value  8 
Fair value - April 30, 2017 $- 
  

2017 Series F Preferred Stock -

Warrant Liability

  2017 Series F Preferred Stock - Embedded Derivative  Total Warrant and Derivative Liability 
Fair value - October 31, 2017 $4,256  $9,246  $13,502 
Change in fair value  (1,731)  (2,083)  (3,814)
Exchange / conversion to common shares  (2,525)  (7,163)  (9,688)
Fair value - April 30, 2018 $-  $-  $- 

 

8.9. STOCK BASED COMPENSATION ARRANGEMENTS

 

Stock-based compensation expense duringIn the three months ended April 30, 2017 and 2016 amounted to approximately $4.2 million and $446,000 respectively. Stock-based compensation expense during the six months ended April 30, 2018 and 2017, and 2016 amounted to approximately $8.6 million and $993,000 respectively. Stock-basedthe Company recorded stock-based compensation expense is recorded in generalrelated to restricted stock awards and administrative expenses in the accompanying consolidated statements of operations.stock options as follows (in thousands):

 

  

For the Three Months Ended

April 30,

 
  2018  2017 
General and administrative expense:        
Continuing operations $5,155  $3,805 
Discontinued operations  -   402 
   5,155   4,207 
Research and development expense:        
Continuing operations  1,465   - 
Total stock-based compensation expense $6,620  $4,207 

On February 8, 2017, the Board appointed Steve Gorlin as a Class II director with a term expiring in 2019 and Dr. Jon Mogford as a Class III director with a term expiring in 2017 to fill vacancies created upon the resignations of Messrs. Brauser and Honig. In addition, Mr. Gorlin was appointed as a member of each of the Board’s Audit, Compensation and Nominating and Corporate Governance Committees. Each of Mr. Gorlin and Dr. Mogford are deemed an “independent” director as such term is defined by the rules of The NASDAQ Stock Market LLC. There are no family relationships between either of Mr. Gorlin and Dr. Mogford and any of our other officers and directors. Mr. Gorlin and Dr. Mogford were each granted (i) an option to purchase up to 50,000 shares of the Company’s common stock at an exercise price equal to $4.72 per share (the “Options”) which Options will vest in 24 equal monthly installments commencing on the one month anniversary of the grant date and (ii) a restricted stock award of 50,000 shares of common stock that will vest in 24 equal monthly installments commencing on the one month anniversary of the grant date (the “RSUs”). The Options and the RSUs were granted pursuant to the Company’s 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan, the vesting and the exercise of the Options and the vesting of the RSUs are subject to stockholder approval.POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

  

For the Six Months Ended

April 30,

 
  2018  2017 
General and administrative expense:        
Continuing operations $14,065  $7,780 
Discontinued operations  -   844 
   14,065   8,624 
Research and development expense:        
Continuing operations  3,687   - 
Total stock-based compensation expense $17,752  $8,624 

 

A summary of the Company’s employee stock option activity in the six months ended April 30, 20172018 is presented below:

 

  

Number of

shares

  

Weighted-Average

Exercise Price

 
Outstanding - October 31, 2016  383,210  $5.74 
Granted  2,715,000  $3.49 
Exercised  (121,698) $4.83 
Outstanding - April 30, 2017  2,976,512  $3.72 
Options exercisable - April 30, 2017  767,342  $4.19 
Weighted-average fair value of options granted during the period     $2.37 

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

  

Number of

shares

  

Weighted-Average

Exercise Price

 
Outstanding - October 31, 2017  3,525,530  $6.34 
Granted  1,127,500  $23.84 
Exercised  (25,794) $3.95 
Forfeited  (34,167) $18.90 
Outstanding - April 30, 2018  4,593,069  $10.55 
Options exercisable - April 30, 2018  2,450,666  $6.76 
Weighted-average fair value of options granted during the period     $16.15 

 

A summary of the Company’s non-employee stock option activity in the six months ended April 30, 20172018 is presented below:

 

  

Number of

shares

  

Weighted-Average

Exercise Price

 
Outstanding - October 31, 2016  -  $- 
Granted  52,000  $4.71 
Outstanding - April 30, 2017  52,000  $4.71 
Options exercisable - April 30, 2017  4,333  $4.71 
  

Number of

shares

  

Weighted-Average

Exercise Price

 
Outstanding - October 31, 2017  293,000  $19.61 
No activity  -  $- 
Outstanding - April 30, 2018  293,000  $19.61 
Options exercisable - April 30, 2018  99,917  $16.21 

 

Stock options are generally granted to employees or non-employees at exercise prices equal to the fair market value of the Company’s common stock at the dates of grant. Stock options generally vest over one to three years and have a term of five to ten years. The total fair value of employee options granted during the six months ended April 30, 2018 was approximately $18.2 million. The intrinsic value of options outstanding at April 30, 2018 was $41.6 million. The intrinsic value of options exercised during the six months ended April 30, 2018 was $344,000. The weighted average remaining contractual term of outstanding and non-employee stock option grants is amortized over the vesting period of, generally, one to three years.exercisable options at April 30, 2018 was 8.9 years and 8.7 years, respectively. As of April 30, 2017,2018, there was approximately $6.3$12.6 million of unrecognized compensation cost related to non-vested employee and non-employee stock option awards,options, which is expected to be recognized over a remaining weighted-average vesting period of 0.80.6 years.

 

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the six months ended April 30, 2017:2018:

 

Risk free annual interest rate  1.78-2.282.01%-2.97%
Expected volatility  71.65-86.3480.86-85.54%
Expected life  5.04-6.005.00-6.01 
Assumed dividends None 

POLARITYTE, INC.

A summary of the Company’sNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Restricted stock and restricted stock units activity for employees and non-employees in the six months ended April 30, 2017 is presented below:2018:

 

  

Number of

shares

  Weighted-Average Grant-Date Fair Value 
Unvested - October 31, 2016  274,829  $6.00 
Granted  1,031,000  $4.56 
Vested  (925,488) $4.00 
Unvested - April 30, 2017  380,341  $6.97 

During the six months ended April 30, 2017, the Company granted 1,031,000 restricted shares to employees and non-employees.

  

Number of

shares

  

Weighted-Average

Grant-Date

Fair Value

 
Unvested - October 31, 2017  227,132  $7.83 
Granted  137,387  $22.02 
Vested  (144,315) $11.82 
Unvested - April 30, 2018  220,204  $14.06 

 

The weighted-averagetotal fair value of restricted sharesstock and restricted stock units granted during the six months ended April 30, 20172018 was $4.56. approximately $3.0 million.

The total fair value of restricted stock granted during the six months ended April 30, 2017 was approximately $4.7 million.

The value ofand restricted stock unit grants is measured based on itsthe fair market value of the Company’s common stock on the date of grant and amortized over the vesting period of, generally, six months to three years. As of April 30, 2017,2018, there was approximately $2.4$1.9 million of unrecognized compensation cost related to unvested restricted stock and restricted stock unit awards, which is expected to be recognized over a remaining weighted-average vesting period of 0.70.5 years.

 

9.10. INCOME TAXES

The Company calculates its provision for federal and state income taxes based on current tax law. The Tax Cuts and Jobs Act (tax reform) was enacted on December 22, 2017 (“Enactment Date”), and has several key provisions impacting accounting for and reporting of income taxes. The most significant provision reduces the U.S. corporate statutory tax rate from 35% to 21% beginning on January 1, 2018. Although most provisions of tax reform are not effective until 2018, the Company is required to record the effect of a change in tax law as of the Enactment Date on its deferred tax assets. As the Company maintains a full valuation allowance against its deferred tax assets, there is no income tax expense recorded related to this change. As of the Enactment Date, the Company estimated that its deferred tax asset and related valuation allowance were each reduced by approximately $2.2 million.

 

Due to the Company’s history of losses and uncertainty of future taxable income, a valuation allowance sufficient to fully offset net operating losses and other deferred tax assets has been established. The valuation allowance will be maintained until sufficient positive evidence exists to support a conclusion that a valuation allowance is not necessary. The Company’s effective tax rate for the six months ended April 30, 2017 and 2016 differed from the expected U.S. federal statutory rate primarily due to the change in the valuation allowance. Full conversionissuance of the outstanding sharesSeries E Preferred Stock in connection with its original acquisition of Preferred Stockthe PolarityTE, Inc., a Nevada corporation in April 2017, will likely result in limitations on the utilization of the Company’s net operating loss carryforwards under IRS section 382.

 

10.11. LOSS PER SHARE

 

Shares of common stock issuable under convertible preferred stock, warrants and options and shares subject to restricted stock grants were not included in the calculation of diluted earnings per common share for the three months and six months ended April 30, 20172018 and 2016,2017, as the effect of their inclusion would be anti-dilutive.

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)For periods when shares of participating preferred stock (as defined in ASC 260 earnings per share) are outstanding, the two-class method is used to calculate basic and diluted earnings (loss) per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. Under the two-class method, basic earnings (loss) per common share is computed by dividing net earnings (loss) attributable to common shares after allocation of earnings to participating securities by the weighted-average number of shares of common stock outstanding during the year. Diluted earnings (loss) per common share, when applicable, is computed using the more dilutive of the two-class method or the if-converted method. In periods of net loss, no effect is given to participating securities since they do not contractually participate in the losses of the Company.

 

The table below provides total potential shares outstanding, including those that are anti-dilutive, on April 30, 20172018 and 2016:2017:

 

 April 30,  April 30, 
 2017  2016  2018  2017 
Shares issuable upon exercise of warrants  -   187,500 
Shares issuable upon conversion of preferred stock  9,281,275   2,956,196   -   9,281,275 
Shares issuable upon exercise of stock options  3,028,512   53,618   4,886,069   3,028,512 
Non-vested shares under restricted stock grants  380,341   164,201   220,204   380,341 

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

11.12. COMMITMENTS AND CONTINGENCIES

 

Contingencies

 

On February 26, 2015, a complaint for patent infringement was filed in the United States District Court for the Eastern District of Texas by Richard Baker, an individual residing in Australia, against Microsoft, Nintendo, the CompanyMajesco Sub, and a number of other game publisher defendants. The complaint allegesalleged that the Company’s Zumba Fitness Kinect game infringed plaintiff’s patents in motion tracking technology. The plaintiff is representing himself pro se in the litigation and is seeking monetary damages in the amount of $1.3 million. The Company, in conjunction with Microsoft, is defending itself against the claim and has certain third-party indemnity rights from developers for costs incurred in the litigation. In August 2015, the defendants jointly moved to transfer the case was subsequently transferred to the Western District of Washington. On May 17, 2016, the Washington Court issued a scheduling order that provides that defendants leave to jointly file an early motion for summary judgementJune 16, 2017, final judgment was entered in June 2016. On June 17, 2016, the defendants jointly filed a motion for summary judgment that stated that nonefavor of the defendants includingfinding that the Company, infringed uponaccused products did not literally infringe the asserted patent.patent and that plaintiff was barred from pursing infringement under the doctrine of equivalents due to prosecution history estoppel. The plaintiff appealed that decision to the Court of Appeals for the Federal Circuit. On JulyApril 9, 2016, Mr. Baker opposed2018, the motion. On July 15, 2016,Court of Appeals for the defendants jointly filed a reply. The briefing onFederal Circuit affirmed the motion is now closed. The Court has not yet issued a decision or indicated if or when there will be oral argument onjudgment of the motion.

Intelligent Verification Systems, LLC (“IVS”), filed a patent infringement complaint on September 20, 2012, in the United States District Court for the EasternWestern District againstof Washington. On May 7, 2018, the plaintiff filed a petition for panel rehearing and rehearing en banc by the Court of Appeals, which is pending. On June 23, 2017, as part of a purchase agreement, liabilities and claims relating to this litigation were assumed by Zift. The Company and Microsoft Corporation. In March 2015,cannot be certain about the court issued an order excludingoutcome of the evidence profferedappeal, or whether litigation regarding the assumption of liabilities by IVS in support of its alleged damages, including the opinion of its damages expert. IVS appealed that decision. On January 19, 2016, the Federal Circuit denied IVS’ appeal and affirmed the district court’s orders that excluded the plaintiff’s damages expert and dismissed the case.Zift may occur.

 

In addition to the item above, the Company at times may be a party to claims and suits in the ordinary course of business. We record a liability when it is both probable that a liability has been incurred and the amount of the loss or range of loss can be reasonably estimated. The Company has not recorded a liability with respect to the matter above. While the Company believes that it has valid defenses with respect to the legal matter pending and intends to vigorously defend the matter above, given the uncertainty surrounding litigation and our inability to assess the likelihood of a favorable or unfavorable outcome, it is possible that the resolution of the matter could have a material adverse effect on our consolidated financial position, cash flows or results of operations.

 

Commitments

 

The Company leases office space in Hazlet, New Jersey at a cost of approximately $1,100 per month under a lease agreement that expires on March 31, 2018.2019.

 

The Company also leasesleased space in Salt Lake City, Utah at a cost of approximately $24,044$24,000 per month under a lease agreement that expired on March 31, 2018. The Company will continue to lease space in Salt Lake City, Utah at a cost of approximately $12,400 per month under a lease agreement that expires on March 31September 30, 2018.

On December 27, 2017, the Company signed a five-year lease with one five-year option to renew on approximately 178,528 rentable square feet in Salt Lake City, Utah. The base rent for the first year of the lease is $1,178,285 and escalates at the rate of 3% per annum thereafter.

Rent expense for the three months ended April 30, 2018 and 2017 was approximately $389,000 and $42,000, respectively. Rent expense for the six months ended April 30, 2018 and 2017 was approximately $638,000 and $60,000, respectively.

 

The Company has entered into employment agreements with key executives that contain severance terms and change of control provisions.

 

12. RELATED PARTIES13. DISCONTINUED OPERATIONS

 

In January 2015,The results of operations from the Company entered into an agreement with Equity Stock Transferdiscontinued business for transfer agent services. A former Board member of the Company is a co-founderthree and chief executive officer of Equity Stock Transfer. Fees under the agreement were approximately $2,000 and $0, in the six months ended April 30, 2018 and 2017 and 2016, respectively.are as follows (in thousands):

 

13. SEGMENT REPORTING

The Company’s operations involve dissimilar products which are managed separately. Accordingly, it operates in two segments: 1) video games and 2) regenerative medicine.

  For the Three Months Ended  For the Six Months Ended 
  April 30,  April 30, 
  2018  2017  2018  2017 
Revenues $-  $259  $-  $415 
Expenses  -   243   -   831 
Gain (loss) from discontinued operations $-  $16  $-  $(416)

POLARITYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

Certain information concerning our segmentsThe cash flows from the discontinued business for the three months and six months ended April 31,30, 2018 and 2017 and 2016 andare as of April 30, 2017 and 2016 is presented in the following tablefollows (in thousands):

 

  Three Months Ended April 30, 
  2017  2016 
Revenues:      
Reportable Segments:        
Video Games $259  $412 
Regenerative Medicine      
Total consolidated revenues $259  $412 
         
Net loss:        
Reportable Segments:        
Video Games $(4,459) $(1,101)
Regenerative Medicine  (105,901)   
Total net loss $(110,360) $(1,101)
  

For the six months ended

April 30,

 
  2018  2017 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss from discontinued operations  -   (416)
Adjustments to reconcile net loss from discontinued operations to net cash used in discontinued operating activities:        
Depreciation and amortization  -   11 
Stock based compensation expense  -   844 
Amortization of capitalized software development costs and license fees  -   50 
Changes in operating assets and liabilities:        
Accounts receivable  -   48 
Accounts payable and accrued expenses  -   10 
Net cash provided by discontinued operating activities  -   547 
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Cash received from sale of Majesco Sub  30   - 
Net cash provided by discontinued investing activities  30   - 

 

  Six Months Ended April 30, 
  2017  2016 
Revenues:      
Reportable Segments:        
Video Games $415  $1,003 
Regenerative Medicine      
Total consolidated revenues $415  $1,003 
         
Net loss:        
Reportable Segments:        
Video Games $(9,425) $(7,750)
Regenerative Medicine  (106,596)   
Total net loss $(116,021)��$(7,750)

14. SUBSEQUENT EVENTS

 

  As of April 30, 2017  As of October 31, 2016 
Identifiable assets employed:        
Reportable Segments:        
Video Games $5,151  $6,751 
Regenerative Medicine  1,895    
Total assets $7,046  $6,751 

Asset Purchase Agreement

 

18

On March 2, 2018, the Company, along with its wholly owned subsidiary, Utah CRO Services, Inc., a Nevada corporation (“Acquisition Co.”), entered into an asset purchase agreement (the “APA”) with Ibex Group, L.L.C., a Utah limited liability company, and Ibex Preclinical Research, Inc., a Utah corporation (collectively, the “Seller”). The transaction closed on May 3, 2018.

Under the APA, the Company purchased from Seller the assets and rights to its preclinical research and veterinary sciences business and related real estate. The business consists of a “good laboratory practices” (GLP) compliant preclinical research facility, including vivarium, operating rooms, preparation rooms, storage facilities, and surgical and imaging equipment.

The purchase price was $1.6 million in cash, of which $266,667 was paid at closing and the balance satisfied by a promissory note. The promissory note payable to Seller is for a total amount of $1,333,333 and is payable in five equal installments beginning on the six-month anniversary of issuance and continuing each six-month anniversary thereafter with interest at the rate of 3.5% per annum.

Purchase and Sale Agreement

Concurrently with the execution and delivery of the APA, on March 2, 2018, the Company entered into a purchase and sale agreement with the Seller to purchase two parcels of real property in Cache County, Utah, consisting of approximately 1.75 combined gross acres of land, together with the buildings, structures, fixtures, and personal property located on the real property (the “Property”). The transaction also closed on May 3, 2018. The purchase price for the Property was $2.0 million, which was paid in cash at closing.

Common Stock Issuance

On June 7, 2018, the Company completed an underwritten offering with Cantor Fitzgerald & Co., as underwriter, providing for the issuance and sale of 2,455,882 shares of the Company’s common stock, par value $0.001 per share, at an offering price of $23.65 per share, for net proceeds of approximately $58 million, after deducting offering expenses payable by the Company.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Statements in this quarterly report on Form 10-Q that are not historical facts constitute forward-looking statements that are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, or the “Exchange Act”. Examples of forward-looking statements include statements relating to industry prospects, our future economic performance including anticipated revenues and expenditures, results of operations or financial position, and other financial items, our business plans and objectives, including our intended product releases, and may include certain assumptions that underlie forward-looking statements. Risks and uncertainties that may affect our future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements include, among other things, those listed under “Riskdiscussed in this section as well as factors described in Part II, Item 1A-“Risk Factors” and elsewhere in our annual report on Form 10-K for the fiscal year ended October 31, 2016.. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are subject to business and economic risk and reflect management’s current expectations and involve subjects that are inherently uncertain and difficult to predict. Actual events or results may differ materially. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of these statements. We are under no duty to update any of the forward-looking statements after the date of this report to conform these statements to actual results. References herein to “we,” “us,” and “the Company” are to PolarityTE, Inc. and its consolidated subsidiaries.

 

Overview

 

PolarityTE, Inc. is an innovative developer, marketer, publishera commercial-stage biotechnology and distributorregenerative biomaterials company focused on transforming the lives of interactive entertainment for consumers around the world. Building on more than 25 years of operating history, the Company developspatients by discovering, designing and publishesdeveloping a wide range of video games on digital networks through its Midnight City label, including Nintendo’s DS, 3DS, Wiiregenerative tissue products and WiiU, Sony’s PlayStation 3biomaterials for the fields of medicine, biomedical engineering and 4, or PS3 and PS4, Microsoft’s Xbox 360 and Xbox One and the personal computer, or PC. The Company sells its products through digital distribution.

PolarityTE, Inc. is aiming to be the first company to deliver regenerative medicine into clinical practice through tissue engineering. Subsequent to the acquisition, the Company’s platform technology will allow it to regenerate a patient’s tissues using their own cells.

Net Revenues. Our revenues are principally derived from sales of our video games.

Cost of Sales. Cost of sales includes amortization and impairment of capitalized software development costs and license fees. Commencing upon the related product’s release, capitalized software development and intellectual property license costs are amortized to cost of sales.

Gross Profit. Gross profit is the excess of net revenues over cost of sales, including amortization and impairment of software development and license fees. Development and license fees incurred to produce video games are generally incurred up front and amortized to cost of sales. The recovery of these costs and total gross profit is dependent upon achieving a certain sales volume, which varies by title.

Product Research and Development Expenses. Ongoing research and development activities have been substantially reduced since fiscal 2014.material sciences.

 

Research and Development – Intellectual Property Acquired.Expenses.On April 7, 2017, as payment for the PolarityTE asset acquisition, the Company issued 7,050 shares of Series E Preferred Stock convertible into an aggregate of 7,050,000 shares of the Company’s common Research and development expenses primarily represent employee related costs, including stock and with a fair value of approximately $104.7 million which is equal to 7,050,000 common shares times $14.85 (the closing price of the Company’s common stock as of April 7, 2017). Since the assets purchased were in-processcompensation, for research and development assets, the total purchase price was immediately expensed as researchexecutives and development – intellectual property acquired since they have no alternative future use.

Sellingstaff, lab and Marketing Expenses. Since July 2015, these activities are now limited to onlineoffice expenses and in social media.other overhead charges.

 

General and Administrative Expenses. General and administrative expenses primarily represent employee related costs, including stock compensation, for corporate executive and support staff, general office expenses, professional fees and various other overhead charges. Professional fees, including legal and accounting expenses, typically represent one of the largest components of our general and administrative expenses. These fees are partially attributable to our required activities as a publicly traded company, such as SEC filings, and corporate- and business-development initiatives.

Depreciation and Amortization Expenses. Depreciation and amortization expenses relate to the Company’s property and equipment which currently consists mostly of recently acquired medical equipment related to the Company’s new medical activities.

Income Taxes. Income taxes consist of our provisions for income taxes, as affected by our net operating loss carryforwards. Future utilization of our net operating loss, or NOL, carryforwards may be subject to a substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code. The annual limitation may result in the expiration of NOL carryforwards before utilization. Due to our history of losses, a valuation allowance sufficient to fully offset our NOL and other deferred tax assets has been established under current accounting pronouncements, and this valuation allowance will be maintained unless sufficient positive evidence develops to support its reversal.

 

Critical Accounting Estimates

 

Our discussion and analysis of the financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP.

 

The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from these estimates under different assumptions or conditions.

 

We have identified the policies below as critical to our business operations and to the understanding of our financial results. The impact and any associated risks related to these policies on our business operations is discussed throughout management’s discussion and analysis of financial condition and results of operations when such policies affect our reported and expected financial results.

 

Revenue Recognition. Our software products are sold exclusively as downloads of digital content for which the consumer takes possession of the digital content for a fee. Revenue from product downloads is generally recognized when the download is made available (assuming all other recognition criteria are met).

When we enter into license or distribution agreements that provide for multiple copies of games in exchange for guaranteed amounts, revenue is recognized in accordance with the terms of the agreements, generally upon delivery of a master copy, assuming our performance obligations are complete and all other recognition criteria are met, or as per-copy royalties are earned on sales of games.

Accounting for Stock-Based Compensation. Stock-based compensation expense is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period. Determining the fair value of stock-based awards at the grant date requires judgment, including, in the case of stock option awards, estimating expected stock volatility. In addition, judgment is also required in estimating the amount of stock-based awards that are expected to be forfeited. If actual results differ significantly from these estimates, stock-based compensation expense and our results of operations could be materially impacted.

 

Accounting for Common and Preferred Stock and Warrant transactions. We issued units consisting of preferred shares and warrants and common stock and warrants and subsequently remeasured certain of those warrants. Determining the fair value of the securities in these transactions requires significant judgment, including adjustments to quoted share prices and expected stock volatility. Such estimates may significantly impact our results of operations and losses applicable to common stockholders.

Commitments and Contingencies. We record a liability for contingencies when the amount is both probable and reasonably estimable. We record associated legal fees as incurred.

 

Results of Operations

 

Three months ended April 30, 20172018 versus three months ended April 30, 20162017

In July 2015, the Company transferred to Zift Interactive LLC (“Zift”), a newly-formed subsidiary, certain rights under certain of its publishing licenses related to developing, publishing and distributing video game products through retail distribution for a term of one year. The Company transferred Zift to its former chief executive officer, Jesse Sutton. In exchange, the Company received Mr. Sutton’s resignation from the position of chief executive officer of the Company, including waiver of any severance payments and the execution of a separation agreement, together with his agreement to serve as a consultant to the Company. In addition, Zift will pay the Company a specified percent of its net revenue from retail sales on a quarterly basis. Approximately $233,000 was paid to Zift during the six months ended April 30, 2016 for consideration under the conveyance agreement with Zift.

 

Net Revenues. Net revenues forFor the three monthsthree-month period ended April 30, 2017 decreased 37% to approximately $259,0002018, net revenues from $412,000 inproduct sales were $3,000, which represents the comparable quarter last year. The decrease was due to lower salessale of Zumba and other titles.

Gross Profit. Gross profit for the three months ended April 30, 2017 decreased 10% to approximately $259,000 compared to a gross profit of approximately $287,000 in the same period last year. The decrease in gross profit reflects lower Zumba and other sales as discussed above. Gross profit as a percentage of net sales was 100% for the three months ended April 30, 2017, compared to 70% for the three months ended April 30, 2016.Company’s core product SkinTE.

 

Product Research and Development Expenses.Cost of Sales. Product research and development expenses forFor the three monthsthree-month period ended April 30, 2017 were2018, cost of sales was approximately $18,000 compared to $20,000$1,000 and represents the freight charges associated with the $3,000 in the same period last year. The decrease reflects the continued reduction in this activity.product sales.

 

Research and Development – Intellectual Property Acquired.Expenses.For the three monthsthree-month period ended April 30, 2017,2018, research and development – intellectual property acquired relates to the PolarityTE asset acquisitionexpenses were approximately $5.6 million. Research and the issuancedevelopment expenses mostly consist of 7,050 shares of Series E Preferred Stock convertible into an aggregate of 7,050,000 shares of the Company’s common stock with a fair valuestock-based compensation of approximately $104.7$1.5 million, which is equal to 7,050,000 common shares times $14.85 (the closing pricesalaries of the Company’s common stock asapproximately $1.7 million, medical studies of April 7, 2017). Since the assets purchasedapproximately $0.3 million, medical samples of approximately $0.2 million, medical equipment depreciation of approximately $0.4 million, rent of approximately $0.4 million, office expense of approximately $0.3 million, business meals and transportation of approximately $0.2 million, consulting of approximately $0.1 million and health insurance of approximately $0.1 million. There were in-processno research and development assets,expenses in the total purchase price was immediately expensed as research and development – intellectual property acquired since there is no alternative future use.

Selling and Marketing Expenses. Total selling and marketing expense for the three months ended April 30,comparable 2017 were approximately negative $7,000 compared to approximately $19,000 for the three months ended April 30, 2016. The current year’s expense was negative due to a cancellation of a public relations service contract.period.

 

General and Administrative Expenses. For the three-month period ended April 30, 2017,2018, general and administrative expenses increased 341% towere approximately $5.8$5.9 million compared to $1.3$5.7 million for the three months ended April 30, 2016.2017. The increase is primarily due to increased stock-based compensation and increased headcount related to the Company’s new medical activities.compensation.

Depreciation and Amortization Expenses.

Other (Expenses) Income. For the three-month period ended April 30, 2018, other (expenses) income mainly included a loss on extinguishment of warrant liability of approximately $520,000 and a change in fair value of derivatives of approximately a $440,000 gain. For the three-month period ended April 30, 2017, depreciation and amortization expenses were approximately $101,000 compared to approximately $7,000other (expenses) income was not significant.

Net Loss from continuing operations. Net loss from continuing operations for the three months ended April 30, 2016. The increase is primarily due to depreciation on recently acquired medical equipment related to the Company’s new medical activities.

Operating loss. Operating loss for the three months ended April 30, 20172018 was approximately $110.4$11.6 million, compared to an operatinga loss of approximately $1.1$110.4 million in the comparable period in 2016,2017, primarily reflecting higherthe decrease of $104.7 million in research and development – intellectual property acquired expenses and stock-based compensation expenses.

Other income.In the three months ended April 30, 2017 and 2016, our other income was not significant.

 

Six months ended April 30, 20172018 versus six months ended April 30, 20162017

 

Net Revenues. Net revenues forFor the six monthssix-month period ended April 30, 2017 decreased 59% to approximately $415,0002018, net revenues from $1.0 million inproduct sales were $16,000, which represents the comparable six months last year. The decrease was due to lower salessale of Zumba and other titles.the Company’s core product SkinTE.

 

Gross Profit.Cost of Sales. Gross profit forFor the six monthssix-month period ended April 30, 2017 decreased 49% to approximately $415,000 compared to a gross profit2018, cost of approximately $820,000 in the same period last year. The decrease in gross profit reflects lower Zumba and other sales as discussed above. Gross profit as a percentage of net sales was 100% forapproximately $2,000 and represents the six months ended April 30, 2017, compared to 82% forfreight charges associated with the six months ended April 30, 2016.$16,000 in product sales.

 

Product Research and Development Expenses. Product research and development expenses for the six months ended April 30, 2017 were approximately $38,000 compared to $55,000 in the same period last year. The decrease reflects the continued reduction in this activity.

Research and Development – Intellectual Property Acquired.Expenses.For the six monthssix-month period ended April 30, 2017,2018, research and development – intellectual property acquired relates to the PolarityTE asset acquisitionexpenses were approximately $12.2 million. Research and the issuancedevelopment expenses mostly consist of 7,050 shares of Series E Preferred Stock convertible into an aggregate of 7,050,000 shares of the Company’s common stock with a fair valuestock-based compensation of approximately $104.7$3.7 million, which is equal to 7,050,000 common shares times $14.85 (the closing pricesalaries of the Company’s common stock asapproximately $3.6 million, medical studies of April 7, 2017). Since the assets purchasedapproximately $0.8 million, bonuses of approximately $0.5 million, medical samples of approximately $0.5 million, medical equipment depreciation of approximately $0.6 million, rent of approximately $0.6 million, office expense of approximately $0.5 million, business meals and transportation of approximately $0.3 million, consulting of approximately $0.2 million and health insurance of approximately $0.2 million. There were in-processno research and development assets,expenses in the total purchase price was immediately expensed as research and development – intellectual property acquired since there is no alternative future use.

Selling and Marketing Expenses. Total selling and marketing expenses for the six months ended April 30,comparable 2017 were approximately $24,000 compared to approximately $42,000 for the six months ended April 30, 2016.period.

 

General and Administrative Expenses. For the six-month period ended April 30, 2017,2018, general and administrative expenses increased 371% towere approximately $11.5$16.8 million compared to $2.4$10.9 million for the six months ended April 30, 2016.2017. The increase is primarily due to increased stock-based compensation and increased headcount related to the Company’s new medical activities.compensation.

21

 

DepreciationOther (Expenses) Income. For the six-month period ended April 30, 2018, other (expenses) income mainly included a change in fair value of derivatives of approximately a $3.8 million gain and Amortization Expenses.a loss on extinguishment of warrant liability of approximately $520,000. For the three-month period ended April 30, 2017, depreciation and amortization expenses were approximately $184,000 compared to approximately $14,000 for the three months ended April 30, 2016. The increase is primarily due to depreciation on recently acquired medical equipment related to the Company’s new medical activities.other (expenses) income was not significant.

Operating loss.Net loss from continuing operations. OperatingNet loss from continuing operations for the six months ended April 30, 20172018 was approximately $116.0$25.7 million, compared to an operatinga loss of approximately $1.7$115.6 million in the comparable period in 2016,2017, primarily reflecting higherthe decrease of $104.7 million in research and development – intellectual property acquired expenses and stock-based compensation expenses.

Other income.In the six months ended April 30, 2017 and 2016, our other income was not significant.

Liquidity and Capital Resources

 

As of April 30, 2017,2018, our cash and cash equivalents balance was $4.8approximately $37.8 million and our working capital was approximately $3.8$35.2 million, compared to cash and cash equivalents of $6.5$17.7 million and working capital of $5.4$2.5 million at October 31, 2016.2017.

 

From fiscal 2013 throughAs reflected in the present,condensed consolidated financial statements, we have experiencedhad an accumulated deficit of approximately $284.7 million at April 30, 2018, a net loss of approximately $25.7 million and approximately $10.0 million net cash outflows from operations, generally to fundused in continuing operating losses due to declining revenues which we attribute to three factors: 1) the introduction of competing “freemium” games on competing handheld devices such as the Apple iPhone or iTouch, and Android powered devices; 2) a shift in game distribution from retail to digital downloads; and 3) a decline in the popularity of motion based fitness games including games we publish under the Zumba fitness brand. As a result of these factors we have reduced our operating expenses, including the reduction of game production and marketing personnel, and have eliminated substantially all of our new game development activities. In 2015, we transferred our retail distribution activities to Zift and transferred related assets and liabilities, including accounts receivable, inventory, customer credits and certain other liabilities.

On December 1, 2016, we entered into an Agreement and Plan of Reorganization (the “Agreement”) with Majesco Acquisition Corp., a Nevada corporation and wholly-owned subsidiary of the Company, PolarityTE, Inc., a Nevada corporation (“Polarity NV”) and Dr. Denver Lough, the owner of 100% of the issued and outstanding shares of capital stock of Polarity NV (the “Seller”). The closing is subject to various closing conditions. We believe we have sufficient cash on hand to fund operations through the next twelve months.

The Company will continue to pursue fundraising opportunities that meet its long-term objectives, however, the Company believes that it has sufficient cash to fund its operations for the next twelvesix months from the issuance of these financial statements.

Dividends

On January 4, 2016, we declared a special cash dividend of an aggregate of $10.0 million to holders of record on January 14, 2016 of its outstanding shares of: (i) common stock (ii) Series A Preferred Shares; (iii) Series B Preferred Shares; (iv) Series C Preferred Shares and (v) Series D Preferred Shares. The holders of record of the Company’s outstanding preferred stock participated in the dividend on an “as converted” basis.

ended April 2016 Registered Common Stock and Warrant Offering30, 2018.

 

On April 13, 2016, the Company entered into12, 2018, we completed a Securities Purchase Agreement with certain institutional investorspublic offering providing for the issuance and sale by the Company of 250,0002,335,937 shares of our common stock, par value $0.001 per shares at an offering price of $16.00 per share, for net proceeds of $34.6 million, after deducting offering expenses payable by us.

On June 7, 2018, we completed an underwritten offering with Cantor Fitzgerald & Co., as underwriter, providing for the Company’sissuance and sale of 2,455,882 shares of our common stock, par value $0.001 per share, at an offering price of $6.00$23.65 per share, for net proceeds of $1.4approximately $58 million, after deducting placement agent feesoffering expenses payable by us.

Based upon the current status of our product development and expenses. In addition,commercialization plans, we believe that our existing cash and cash equivalents will be adequate to satisfy our capital needs to approximately October 2020. We anticipate needing substantial additional financing to continue clinical deployment and commercialization of our lead product SkinTE, development of our other product candidates, and scaling the Company soldmanufacturing capacity for our products and product candidates, and prepare for commercial readiness. We will continue to purchaserspursue fundraising opportunities when available, however, such financing may not be available on terms favorable to us, if at all. If adequate funds are not available, we may be required to delay, reduce the scope of, common stock in this offering, warrantsor eliminate one or more of our product development programs. We plan to purchase 187,500 sharesmeet our capital requirements primarily through issuances of its common stock. The common sharesequity securities, debt financing, revenue from product sales and future collaborations. Failure to generate revenue or raise additional capital would adversely affect our ability to achieve our intended business objectives.

Our actual capital requirements will depend on many factors, including among other things: our ability to scale the manufacturing for and to commercialize successfully our lead product, SkinTE; the progress and success of clinical evaluation and acceptance of SkinTE; our ability to develop our other product candidates; and the Warrant Shares were offered bycosts and timing of obtaining any required regulatory registrations or approvals. Our forecast of the Company pursuantperiod of time through which our financial resources will be adequate to an effective shelf registrationsupport our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. The foregoing factors, along with the other factors described in the section, Item 1A, “Risk Factors” in Part II of this Report on Form S-3,10-Q as well as our risk factors set forth in our Annual Report on Form 10-K for the year ended October 30, 2017, will impact our future capital requirements and the adequacy of our available funds. If we are required to raise additional funds, any additional equity financing may be highly dilutive, or otherwise disadvantageous, to existing stockholders and debt financing, if available, may involve restrictive covenants. Collaborative arrangements, if necessary to raise additional funds, may require us to relinquish rights to certain of our technologies, products or marketing territories. Our failure to raise capital when needed, and on acceptable terms, would require us to reduce our operating expenses and would limit our ability to respond to competitive pressures or unanticipated requirements to develop our product candidates and to continue operations, any of which was initially filed withwould have a material adverse effect on our business, financial condition and results of operation.

As previously reported, we identified a material weakness in the Securitieseffectiveness of our internal controls over financial reporting, a factor that could affect our liquidity and Exchange Commission on October 22, 2015 and declared effective on December 7, 2015. The closingcapital resources. At present, management believes that the recent improvement of the offering occurred on April 19, 2016.

Each Warrant is immediately exercisableprocesses for two years, but not thereafter, at an exercise price of $6.90 per share. Subjectgranting equity awards to limited exceptions, a holder of warrantscertain employees and service providers will not haveultimately correct the right to exercise any portion of its warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to such exercise. The exercise price and number of warrants are subject to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization, reorganization or similar transaction.material weakness.

 

Preferred Share Conversion ActivityCommon Stock

 

During the six months ended April 30, 2017, 3,336,700 shares of Convertible Preferred Stock Series A, 6,092 shares of Convertible Preferred Stock Series B, 5,648 shares of Convertible Preferred Stock Series C and 96,332 shares of Convertible Preferred Stock Series D were converted into 971,860 shares of common stock.

During the six months ended April 30, 2016, 599,634 shares of Convertible Preferred Stock Series A and 12,001 shares of Convertible Preferred Stock Series D were converted into 119,941 shares of common stock.

Common Stock

On January 4, 2016, the Company declared a special cash dividend of an aggregate of $10.0 million to holders of record on January 14, 2016 of its outstanding shares of: (i) common stock (ii) Series A Convertible Preferred Stock; (iii) Series B Convertible Preferred Stock; (iv) Series C Convertible Preferred Stock and (v) Series D Convertible Preferred Stock. The holders of record of the Company’s outstanding preferred stock participated in the dividend on an “as converted” basis.

On January 6, 2016,2018, certain investorsemployees exercised their options at $4.08a weighted-average exercise price of $3.95 in exchange for the Company’s common stock for an aggregated amount of 31,65625,417 shares.

Exchange of 100% of Outstanding Series F Preferred Stock Shares and Warrants

On December 16, 2016,September 20, 2017, the Company sold an aggregate of 759,333$17,750,000 worth of units (the “Units”) of the Company’s securities to accredited investors at a purchase price of $2,750 per Unit with each Unit consisting of (i) one share of the Company’s newly authorized 6% Series F Convertible Preferred Stock, par value $0.001 per share (the “Series F Preferred Shares”), which are each convertible into one hundred (100) shares of itsthe Company’s common stock, and (ii) a two-year warrant to certain accredited investors pursuant to separate subscription agreementspurchase 322,727 shares of the Company’s common stock, at aan exercise price of $3.00$30.00 per share.

The Series F Preferred Shares were convertible into shares of the Company’s common stock based on a conversion calculation equal to the stated value of the Series F Preferred Shares, plus all accrued and unpaid dividends, if any, on such Series F Preferred Shares, as of such date of determination, divided by the conversion price. The stated value of each Series F Preferred Share was $2,750 and the initial conversion price is $27.50 per share, each subject to adjustment for gross proceeds of $2.3 million.stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events.

 

On January 18, 2017,the two (2) year anniversary of the initial issuance date, any Series F Preferred Shares outstanding and not otherwise already converted, shall, at the option of the holder, either (i) automatically convert into common stock of the Company at the conversion price then in effect or (ii) be repaid by the Company based on the stated value of such outstanding Series F Preferred Shares.

On March 6, 2018, the Company entered into separate exchange agreements (each an(the “Exchange Agreement”Agreements”) with certain accredited investors (the “Investors”holders (each a “Holder”, and collectively the “Holders”) who purchasedof 100% of the Company’s outstanding Series F Preferred Shares, and the Company’s warrants to purchase shares of the Company’s common stock issued in connection with the Series F Preferred Shares (such “Warrants” and Series F Preferred Shares collectively referred to as the “Exchange Securities”) to exchange the Exchange Securities and unpaid dividends on the Series F Preferred Shares, for common stock (the “Warrants”“Exchange”).

The Exchange resulted in the following issuances: (A) all outstanding Series F Preferred Shares were converted into 972,070 shares of restricted common stock at an effective conversion price of $18.26 per share of common stock (the closing price of Common Stock on the NASDAQ Capital Market on February 26, 2018); (B) the right to receive 6% dividends underlying Series F Preferred Shares was terminated and in exchange 31,321 shares of restricted common stock were issued; (C) 322,727 Warrants to purchase common stock were exchanged for 151,871 shares of restricted common stock; and (D) the Holders of the Warrants relinquished any and all other rights pursuant to the prospectus dated April 13, 2016. PursuantWarrants, including exercise price adjustments.

As part of the Exchange, the Holders also relinquished any and all other rights related to the Offering,issuance of the Exchange Securities, the respective governing agreements and certificates of designation, including any related dividends, adjustment of conversion and exercise price, and repayment option. The existing registration rights agreement with the holders of the Series F Preferred Shares was also terminated and the holders of the Series F Preferred Shares waived the obligation of the Company issued 250,000to register the common shares issuable upon conversion of Series F Preferred Shares or upon exercise of the Warrants, and waived any damages, penalties and defaults related to the Company failing to file or have declared effective a registration statement covering those shares.

Preferred Stock Conversion and Elimination

On February 6, 2018, 15,756 Series B Preferred Shares were converted into 262,606 shares of common stock.

On March 6, 2018, the Company’s common stockCompany received conversion notices from holders of 100% of the outstanding Series A Preferred Shares, Series B Preferred Shares and Warrants to purchase 187,500Series E Preferred Shares and issued an aggregate of 7,945,250 shares of common stock (takingto such holders.

The Series E Preferred Shares were held by Dr. Denver Lough, the Company’s Chief Executive Officer. On March 6, 2018, the Company entered into accounta new registration rights agreement (the “Lough Registration Rights Agreement”) with Dr. Denver Lough, pursuant to which the reverse splitCompany agreed to file a registration statement to register the resale of 7,050,000 shares of Common Stock issued upon conversion of the Company’s common stock on a 1 for 6 basisSeries E Preferred Shares within six months, to cause such registration statement to be declared effective with The NASDAQ Stock Market LLC on August 1, 2016). The common stock and Warrants were offered by the CompanySecurities and Exchange Commission as promptly as possible following its filing and, with certain exceptions set forth in the Lough Registration Rights Agreement, to maintain the effectiveness of the registration statement until all of such shares have been sold or are otherwise able to be sold pursuant to an effective shelfRule 144 under the Securities Act without restriction. Any sales of shares under the registration statement.statement are subject to certain limitations as specified with more particularity in the Lough Registration Rights Agreement.

 

Under

On March 7, 2018, the termsCompany filed a Certificate of Elimination with the Secretary of State of the Exchange Agreement, each Investor exchanged each Warrant it purchased inState of Delaware terminating the Offering for 0.3Company’s Series A, Series B, Series C, Series D, Series E and Series F Preferred Stock. As a result, the Company has 10,000,000 shares of common stock. Accordingly, the Company issued an aggregate of 56,250 shares of commonauthorized and unissued preferred stock in exchange for the return and cancellation of 187,500 Warrants.with no designation as to series.

During the six months ended April 30, 2017, certain employees exercised their options at a weighted-average exercise price of $4.83 in exchange for the Company’s common stock for an aggregated amount of 121,698 shares.

 

Off-Balance Sheet Arrangements

 

As of April 30, 2017,2018, we had no off-balance sheet arrangements.

 

Inflation

 

Our management currently believes that inflation has not had, and does not currently have, a material impact on continuing operations.

Cash Flows

 

Cash and cash equivalents and working capital were approximately $4.8$37.8 million and $3.8$35.2 million, respectively, as of April 30, 20172018 compared to cash and cash equivalents and working capital of approximately $6.5$17.7 million and $5.4$2.5 million at October 31, 2016,2017, respectively.

 

Operating Cash Flows. Cash used in continuing operating activities in the six months ended April 30, 20172018 amounted to approximately $10.0 million compared to approximately $2.7 million compared to approximately $1.0 million for the 20162017 period. The increase in net cash used in continuing operating activities mostly relates to the increaseincreases in net loss, partially offset by theboth research and development – intellectual property acquired paidand general and administrative expenses.

Cash provided by discontinued operating activities in the six months ended April 30, 2018 amounted to approximately $0 compared to approximately $547,000 for the same period in preferred shares.2017.

 

Investing Cash Flows. Cash used in continuing investing activities in the six months ended April 30, 20172018 amounted to approximately $2.0 million. The$4.5 million compared to $2.0 million for the 2017 period. For both the 2018 and 2017 periods, the activity relates to the purchase of property and equipment (mostly medical equipment). There were no investing activities in the 2016 period.

 

Financing Cash Flows.Flows. Net cash provided by financing activities for the six months ended April 30, 20172018 amounted to approximately $34.7 million compared to approximately $2.9 million compared to approximately $8.7for the 2017 period. The $34.6 million used in 2016 period. Fornet proceeds from the sale of common stock in the six months ended April 30, 2017,2018, accounts for the $2.9 million relatedmajority of that periods financing activity and accounts for the majority of the increase in net cash proved by financing activities as compared to capital raising activities and proceeds from option exercises. For the six months ended April 30, 2016, the $8.7 million mostly related to a payment of a $10.0 million special cash dividend, partially offset by an equity capital raise of approximately $1.4 million.comparable prior year period.

Recent Accounting Pronouncements

 

Refer to our discussion of recent accounting pronouncements in Note 2 - Summary of Significant Accounting Policies to the accompanying condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Item 3. Quantitative and Qualitative Disclosure about Market Risk

 

Not applicable.

 

Item 4. Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as defined in the Securities Exchange Act of 1934 Rule 13a-15(e) and 15d-15(e), as of the end of the period covered by this report.

In designing and evaluating our disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

While

A material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board (“PCOAB”) Audit Standard No. 5, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Under the caption “Item 4. Controls and Procedures” of our report on Form 10-Q for the quarter ended January 31, 2018, filed with the Securities and Exchange Commission on March 19, 2018, we believe our disclosure controls and procedures andreported a material weakness in our internal control over financial reporting. Specifically, due to a lack of processes in place to address personnel changes, controls over the Company’s process of accounting for stock-based compensation failed to ensure the completeness of stock options and restricted stock grants in the Company’s calculation of stock-based compensation expense. In addition, due to a lack of adequate review and reconciliation control procedures, the Company’s internal control over financial reporting are adequate, no systemfailed to prevent adjustments to the Company’s financial statements in the quarter ended January 31, 2018, with respect to certain costs not material in amount that we expensed, which should have been capitalized and classified as fixed assets.

During the quarter ended January 31, 2018, we started the process to mitigate the material weakness in our process of controls can prevent errorsaccounting for stock-based compensation, and fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance thatwe expect it to be remediated during fiscal year 2018. At the control system’s objectives will be met. Further,end of April 2018, we engaged the designservices of a control system must reflect the fact that there are resource constraints,third party accounting advisory firm to provide assistance in developing more effective processes and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issuesrecording and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty,classifying expenditures, and that breakdowns can occur. Controls can also be circumvented by individual acts of some people, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events,reviewing and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with its policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.making appropriate period-end adjustments.

Subject to the limitations above, management believes that the condensed consolidated financial statements and other financial information contained in this report, fairly present in all material respects our financial condition, results of operations, and cash flows for the periods presented.

Based on the evaluation of the effectiveness of our disclosure controls and procedures and the material weaknesses identified above that have not yet been remediated, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were not effective at a reasonable assurance level.level at April 30, 2018.

 

Changes in Internal Control Over Financial Reporting

 

During the three months ended April 30, 2017,2018, there were no changes in our internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

On February 26, 2015, a complaint for patent infringement was filed in the United States District Court for the Eastern District of Texas by Richard Baker, an individual residing in Australia, against Microsoft, Nintendo, the CompanyMajesco Sub, and a number of other game publisher defendants. The complaint allegesalleged that the Company’s Zumba Fitness Kinect game infringed plaintiff’s patents in motion tracking technology. The plaintiff is representing himself pro se in the litigation and is seeking monetary damages in the amount of $1.3 million. The Company, in conjunction with Microsoft, is defending itself against the claim and has certain third-party indemnity rights from developers for costs incurred in the litigation. In August 2015, the defendants jointly moved to transfer the case was subsequently transferred to the Western District of Washington. On May 17, 2016, the Washington Court issued a scheduling order that provides that defendants leave to jointly file an early motion for summary judgementJune 16, 2017, final judgment was entered in June 2016. On June 17, 2016, the defendants jointly filed a motion for summary judgment that stated that nonefavor of the defendants includingfinding that the Company, infringed uponaccused products did not literally infringe the asserted patent.patent and that plaintiff was barred from pursing infringement under the doctrine of equivalents due to prosecution history estoppel. The plaintiff appealed that decision to the Court of Appeals for the Federal Circuit. On JulyApril 9, 2016, Mr. Baker opposed2018, the motion.Court of Appeals for the Federal Circuit affirmed the judgment of the District Court for the Western District of Washington. On July 15, 2016,May 7, 2018, the defendants jointlyplaintiff filed a reply.petition for panel rehearing and rehearing en banc by the Court of Appeals, which is pending. On June 23, 2017, as part of a purchase agreement, liabilities and claims relating to this litigation were assumed by Zift. The briefing onCompany cannot be certain about the motion is now closed. The Court has not yet issued a decisionoutcome of the appeal, or indicated if or when there will be oral argument onwhether litigation regarding the motion.assumption of liabilities by Zift may occur.

 

In addition to the item above, the

The Company at times may be a party to claims and suits in the ordinary course of business. We record a liability when it is both probable that a liability has been incurred and the amount of the loss or range of loss can be reasonably estimated. The Company has not recorded a liability with respect to the matter above. While the Company believes that it has valid defensesdivested liability with respect to the legal matter pending and intends to vigorously defend the matter above, given the uncertainty surrounding litigation and our inability to assess the likelihood of a favorable or unfavorable outcome, it is possible that the resolution of the matter could have a material adverse effect on our consolidated financial position, cash flows or results of operations.

Item 1A. Risk Factors

The following updates certain risk factors set forth in our Annual Report on Form 10-K, for the year ended October 31, 2017, as amended and restated in our Quarterly Report on Form 10-Q for the period ended January 31, 2018, filed with the Securities and Exchange Commission on March 19, 2018, and should be read in conjunction with the risk factors presented in Part II of that Quarterly Report under the caption “Item 1A. Risk Factors.”

We have a history of operating losses and may never achieve or sustain profitability.

 

None.We have to date incurred, and may continue to incur significant operating losses over the next several years. We have incurred significant net losses in each year since our inceptions, and have a net loss of $130.8 million for the year ended October 31, 2017, and $25.7 million for the six months ended April 30, 2018. Our ability to achieve profitable operations in the future will depend in large part upon the successful development and commercialization of our product candidates and technologies. Factors impacting our ability to successfully develop and commercialize our product candidates include:

approvals by and/or registrations with the FDA and other US and foreign government agencies;
our ability to educate and train physicians and hospitals on the benefits of our product candidates;
the rate at which providers adopt our technology and product candidates;
our ability to scale up our global commercialization, including our selling and manufacturing activities;
our ability to complete the development of our product candidates in a timely manner;
our ability to obtain adequate reimbursement from third parties for our products and product candidates; and
other activities generally necessary in order to introduce and bring new products and medical technologies to market.

The likelihood of the long-term success of our company must be considered in light of the expenses, difficulties and delays frequently encountered in the development and commercialization of new and innovative medical techniques and technologies, unknown and uncertain regulatory hurdles for a new and novel technology or technique, competitive factors and competition, as well as the uncertain nature of new business development and ongoing capital requirements.

If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results.

Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required to report upon the effectiveness of our internal control over financial reporting. We will be an “accelerated filer,” as defined in the Exchange Act, for the fiscal year beginning November 1, 2018. Consequently, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting in the form of an opinion on the effectiveness of our internal controls over financial reporting as of October 31, 2018. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation of deficiencies. To comply with the requirements of being a reporting company under the Exchange Act, we need to upgrade our systems including information technology; implement additional financial and management controls, reporting systems, and procedures; and ensure we have hired sufficient accounting and finance staff.

We have identified a material weakness in our internal control over financial reporting. If our remedial measures are insufficient to address the material weakness, or if we otherwise fail to establish and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results, timely file our periodic reports, maintain our reporting status or prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly. In addition, we cannot be certain that material weaknesses or significant deficiencies in our internal controls will not be discovered in the future.

Our October 31, 2017 financial statements were prepared on a going concern basis.

In its report dated January 29, 2018, related to our October 31, 2017 consolidated financial statements, EisnerAmper LLP, our independent registered public accounting firm, expressed substantial doubt about our ability to continue as a going concern as we had suffered recurring losses from operations and had insufficient liquidity to fund our future operations. If we were unable to improve our liquidity position we may not be able to continue as a going concern.

As of April 30, 2018, we had $37.8 million of cash.

On June 7, 2018, the Company completed an underwritten offering with Cantor Fitzgerald & Co., as underwriter, providing for the issuance and sale of 2,455,882 shares of the Company’s common stock, par value $0.001 per share, at an offering price of $23.65 per share, for net proceeds of approximately $58 million, after deducting offering expenses payable by the Company. We anticipate that our principal sources of liquidity will be sufficient to fund our activities through approximately October 2020.

In order to have sufficient cash to fund our operations, we will need to continue to raise additional equity or debt capital and we cannot provide any assurance that we will be successful in doing so.

We may not be able to raise the required capital to conduct our operations and develop and commercialize our product candidates.

We incurred net losses of $130.8 million in fiscal 2017, and additional net losses of $25.7 for the six months ended April 30, 2018. We will require substantial additional capital resources in order to complete our product development programs, complete clinical trials, and market and commercialize our product candidates. In order to grow and expand our business, and to introduce our new product candidates into the marketplace, we will need to raise a significant amount of additional funds. We will also need significant additional funds or a collaborative partner, or both, to finance the research and development activities. Accordingly, we are continuing to pursue additional sources of financing.

Our future capital requirements will depend on numerous factors, including:

our ability to generate future revenues;
costs and timing of our product development activities;
timing of conducting pre-clinical and clinical trials and seeking regulatory approvals and/or registrations;
our ability to commercialize our product candidates;
our ability to avoid infringement and misappropriation of third-party intellectual property;
our ability to obtain valid and enforceable patents;
competing technological and market developments;
our ability to establish collaborative relationships;
market acceptance of our product candidates;
the development of an infrastructure to support or business;
our need to remediate material weaknesses and implement and maintain additional internal systems, processes and infrastructure, to have an effective system of internal control over financial reporting;
our ability to scale up our production capabilities for larger quantities of our products; and
our ability to control costs.

We expect to devote substantial capital resources to, among other things, fund operations, continue development programs, and to build out and increase our portfolio of product candidates. If we are unable to secure such additional financing, it will have a material adverse effect on our business and we may have to limit operations in a manner inconsistent with our development and commercialization plans. If additional funds are raised through the issuance of equity securities or convertible debt securities, it will be dilutive to our stockholders and could result in a decrease in our stock price.

We have funded our operations primarily with proceeds from public and private offerings of our common stock. Our history of operating losses and cash uses, our projections of the level of cash that will be required for our operations to reach profitability, and the restricted availability of credit for emerging industries, may impair our ability to raise capital on terms that we consider reasonable and at the levels that we will require over the coming months. We cannot provide any assurances that we will be able to secure additional funding from public or private offerings on terms acceptable to us, if at all. If we are unable to obtain the requisite amount of financing needed to fund our planned operations, it would have a material adverse effect on our business and ability to continue as a going concern.

If adequate funds are not available in the future, we may not be able to develop or enhance our product candidates, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements and we may be required to delay or terminate research and development programs, curtail capital expenditures, and reduce business development and other operating activities. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, the consequences could have a material adverse effect on our business, operating results, financial condition and prospects.

Our executive officers and directors have the ability to control matters submitted to stockholders for approval.

On March 6, 2018, Dr. Denver Lough converted 7,050 shares of our Series E Preferred Stock into 7,050,000 shares of our common stock and received a proxy to vote an additional 797,296 shares of common stock held by certain of our other shareholders. Dr. Lough holds additional shares and/or vested options to purchase shares of our common stock. As of June 13, 2018, there were 21,304,370 shares of common stock issued and outstanding eligible to vote and, accordingly, Dr. Lough currently holds or has the right to vote approximately 41% of the outstanding voting capital of the Company. As a result, Dr. Lough, together with our other executive officers and directors, would likely be able to cast enough votes to determine the outcome of any proposal submitted to the stockholders of the Company for a vote.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.During the three months ended April 30, 2018, certain employees exercised their options at a weighted-average exercise price of $3.95 in exchange for the Company’s common stock for an aggregated amount of 25,417 shares. The shares were issued in reliance on the exemption from registration set forth in Section 4(a)(2) of the Securities Act of 1933, as amended.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

31.1*Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32*Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*XBRL Instance Document.
101.SCH*XBRL Schema Document.
101.CAL*XBRL Calculation Linkbase Document.
101.DEF*XBRL Definition Linkbase Document.
101.LAB*XBRL Label Linkbase Document.
101.PRE*XBRL Presentation Linkbase Document.

 

* Filed herewith.herewith

 

 2527 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

POLARITYTE, INC.

 

 /s/ Denver Lough 
 Denver Lough 
 

Chief Executive Officer

 
 (Principal Executive Officer) 
Date:June 9, 201714, 2018 
   
 /s/ John Stetson 
 John Stetson 
Title:Chief Financial Officer 
 (Principal Financial and Accounting Officer) 
Date:June 9, 201714, 2018 

28